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Merging synthetic polymers with potent biomolecules is an effective strategy to build 
hybrid systems that benefit from the best of both worlds. However, the combination 
of polymers with biomolecules bearing strong appeal for biomedical applications, e.g., 
enzymes producing therapeutic compounds or detectable signals as diagnostic 
indicators, is often compromised due to the properties of the polymers not matching 
the requirements for the incorporation of the said active biomolecules. Hence, bio-
hybrid polymer nanosystems have yet to develop their full potential for biomedical 
applications.  
Chapter 1 introduces the concept of mimicking compartmentalization of biological 
cells by the means of synthetic polymers able to build nanocompartments with a large 
potential for accommodating various biomolecules. An overview of polymer 
properties, self-assembly of amphiphilic block-copolymers and polymersome 
formation techniques, as well as target applications of bio-hybrid nanocompartments 
is given. Finally, strategies to overcome drawbacks of such hybrid systems are 
introduced. 
Chapter 2 describes the aim of this work which is to set stage for biomedical 
applications involving innovative catalytic nanocompartments encapsulating 
enzymes. The targeted applications and adopted strategies to develop different bio-
hybrid systems are presented.  
Chapter 3 highlights the development of a theranostic polymersome-based super 
assembly aimed at providing a novel type of treatment for atherosclerosis. Separate 
imaging and therapeutic nanocompartments were tethered together via hybridizing  
surface-exposed, complementary DNA strands, to form dual-functional polymersome 
clusters with simultaneous therapeutic and imaging properties. On one hand, on-site 
dopamine production was achieved by therapeutic compartments encapsulating active 
Dopa Decarboxylase (DDC), which are permeabilized by membrane insertion of OmpF 
porin. On the other hand, imaging compartments containing fluorescent dyes enabled 
tracking of the complete super-assemblies in parallel to their attachment to epithelial 





this system represents a novel platform for future dual-functional systems aiming at 
other biomedical applications. 
Chapter 4 presents a polymersome-based bioluminescent system that is able to 
produce a strong and long-lasting light signal as is desired for pre-clinical imaging 
applications. The encapsulation of Gaussia Luciferase (GLuc) within the cavity of 
polymersomes enabled efficient light production. The diffusion of GLuc substrate 
thought the membrane-inserted OmpF was exploited to modulate the enzyme kinetics 
such that the signal turned long-lasting. The applicability of such a system was 
investigated in vitro in cultured cells and in vivo in a mouse model. 
Chapter 5 illustrates how mimicking native organelles can be exploited to provide a 
novel bio-hybrid system showing cell-photoprotective potential. Melanosome mimics 
were developed via encapsulation of Tyrosinase together with precursors L-
DOPA/Dopamine to form macromolecular melanin/polydopamine (PDA) within the 
cavity of polymersomes. By enclosing the melanin/PDA production, the polymeric 
membrane prevents the major pitfalls associated with synthetic melanin/PDA 
nanoparticles and enables a bio-hybrid system with reduced cytotoxicity and 
enhanced colloidal stability while UV-absorption properties are preserved. 
Finally, the mix and match of strategies employed to build the different bio-hybrid 
systems, the challenge of balancing the polymer/biomolecules selection with the 
design and optimization possibilities, and the potential of the resulting bio-hybrid 
systems to evolve into novel biomedical applications are discussed (chapter 6). 
Complementary material including additional experimental details (chapter 7), 
relevant literature (chapter 8), contributor and funding acknowledgment (chapter 
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This chapter explores the various approaches in which biomolecules can be combined 
with synthetic polymeric systems to obtain advanced bio-hybrid materials. First, an 
overview on the polymers used for capsule and vesicle formation, their properties 
and the methods for self-assembly and capsule preparation is provided. Next, recent 
advances in the development of nano-sized polymersomes combined with different 
biomolecules, e.g., peptides, antibodies, proteins/enzymes, nucleic acids, sugars or 
lipids as biological components are presented, with the focus on catalytic bio-hybrid 
systems. Finally, targeted biomedical applications of bio-hybrid polymersomes as 
well as current limitations and possible improvement strategies are addressed. 
Assemblies of natural polymers like chitosan or alginate, or those primarily 
composed of polymeric biomolecules like peptides or DNA, are excluded as they are 
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This chapter contains parts adapted with permission from the review1 
C. E. Meyer, S. Abram, I. Craciun, C. G. Palivan, Biomolecule-polymer hybrid 
compartments: combining the best of both worlds, Physical Chemistry Chemical 





1.1 Compartmentalization: mimicking nature to reach function  
1.1.1 Cellular compartmentalization 
Compartmentalization is a central characteristic of biological functions as it intervenes 
at different level of cellular life (Figure 1.1): cells are the most prominent example of 
a biological compartment as their inner aqueous content is separated from the external 
environment via a thin phospholipidic membrane, forming a micro-meter-sized 
vesicle.2 As a result, cell individuality is achieved as specific cellular material is set 
apart from the extra-cellular environment and neighboring cells. Additionally, an 
increased level of complexity is achieved for eukaryotic cells, which are individually 
sub-compartmentalized, e.g., in the form of organelles, to perform multiple functions 
by isolation of distinct chemical reactions. The compartmentalization strategy is also 
exploited for cell-cell communication, where membrane-derived sub-micro-meter 
vesicles that encapsulate relevant biomolecules act as shuttle to deliver signals, 
highlighting the protective and directive character of these compartments. Thus, 
compartmentalization is a fundamental principle in biology that is needed for the 
temporal and spatial separation required for the control of chemical reactions and/or 
of incompatible biomolecules. For this reason, compartmentalization is placed at the 
center of numerous studies aiming to mimic or hijack biological functions.  






1.1.2 Mimicking biological compartments 
Synthetic compartments have emerged as a way to mimic biological compartments. 
Their contents (specific biomolecules) can be controlled in order to reach desired 
applications ranging from model of study to therapeutic cargos. Liposomes, spherical 
vesicles made of phospholipids, have been the spearhead for the development of 
micrometer-sized artificial vesicles used as artificial cells.3 Beyond that, their 
nanometer-sized analogues have gained particular interest in drug delivery because 
therapeutic payloads can be encapsulated inside the vesicles’ lumen. At the same time, 
stealth or targeting agents can be anchored in the vesicle membrane or attached to 
their surface.4 Liposomes benefit from great intrinsic biocompatibility and 
biodegradability, as they consist of phospholipids. Thus they closely resemble 
biological compartments and easily accommodate a wide variety of biomolecules. 
However, with regard to applications, their mechanical properties as well as their 
restricted chemical versatility lessen their potential.5 
The formation of nano- and micro-sized compartments was also demonstrated 
for synthetic polymers.6,7 These polymeric compartments represent an attractive 
alternative to liposomes as they demonstrate greater chemical versatility and 
enhanced robustness due to their thicker membrane while, when appropriately 
selected, they maintain the softness typical for liposomes. Despite their thicker 
membrane, the flexibility of polymersomes allows for the incorporation of 
biomolecules which remain functional.8,9 In addition, the progress in polymer 
chemistry yielded to a variety of copolymers with tailored properties and excellent 
biocompatibility that can compete with the intrinsic biocompatibility and 
biodegradability of natural polymers.10 The precise chemical tuning, e.g., length, 
charge, or responsiveness, and the possibility of easy functionalization with reactive 
moieties for bioconjugation makes synthetic copolymers great building blocks for bio-







1.2 Polymer-based bio-hybrid compartments  
1.2.1 Biomolecules within polymeric compartments 
Polymer-based bio-hybrid compartments integrate biomolecules for their specific 
functionality into their polymeric scaffold and thus combine the advantages of 
biological with synthetic systems. The different biological components (nucleic acids, 
carbohydrates, peptides, proteins)11–14 can be (I) attached to the compartment’s 
surface, (II) encapsulated inside the cavity or (III) integrated into its membrane 
(Figure 1.2). Thereby, these different classes of biomolecules can be simultaneously 
exploited for their intrinsic functions at different locations of the compartment. For 
example, a targeting peptide on the surface can be combined with encapsulated siRNA 
cargo or a channel protein embedded in the synthetic membrane which allows the 
access of substrates to an enzyme encapsulated in the cavity. Another interesting way 
to obtain biohybrids is to encapsulate nano-sized liposomes inside micro-sized 
polymeric vesicles. Thus, the localization and the type of biomolecules have to be 







Figure 1.2. Schematic representation of the different types of biomolecules and their possible 





1.2.2 Size of bio-hybrid compartments 
The size of the polymeric compartment plays an essential role in the applicability of 
the entire bio-hybrid system. Micro-meter-size bio-hybrid compartments usually 
serve as cell mimic for studying biological reactions such as enzymatic cascade 
reactions or actin polymerization.15–17 These cell-sized polymeric compartments also 
bear the possibility to be sub-compartmentalized via encapsulation of sub-micro-
meter counterparts, resulting in multicompartments that more closely mimic 
biological cells.15,16 On the other hand, nano-meter-sized bio-hybrid compartments 
lean towards more applied goals such as therapeutic/sensing/imaging applications, as 
their dimensions are compatible with intravenous injection and cell-uptake. However, 
it has to be noted that the shape and charge of the compartments are also primordial 
to determine their applicability, e.g., for cell uptake/attachment. 
 
1.2.3 Polymers used to form bio-hybrid compartments 
The choice of the polymer is also crucial, as its overall physico-chemical properties, 
ability to incorporate biomolecules, and associated procedure of compartment 
formation considerably influence the function of the final bio-hybrid system. The type 
of compartment differs depending on the kind of synthetic polymers used: 
polyelectrolytes can self-assemble into a membrane enclosing an aqueous volume, 
based on the ionic interactions of oppositely charged polymers forming polyion 
complex (PIC)18 vesicles called PICsomes (Figure 1.3). The two interacting polymers 
are not covalently linked. Usually, one anionic and one cationic PEG-poly(amino 
acid)-block copolymer are simply mixed in aqueous solution and assemble into 
semipermeable unilamellar membranes with PEG units on both sides.19 PICsomes 
benefit from a simple preparation procedure in a purely aqueous environment 
together with intrinsic biocompatibility of the poly(amino acids) part, which are good 
prerequisites for the encapsulation of active biomolecular cargos. However, 
mechanical stress and changes in pH/ionic strength can cause the reversible 
disassembly of the vesicular structure or increase its permeability. Thus, the 
compromised stability under physiological conditions, as well as the improvement of 
mechanical properties via crosslinking that can be detrimental to incorporated 





Another kind of polymeric compartment, called Layer-by-Layer (LbL) capsules, 
can also be formed using two different polymers that interact by electrostatic forces or 
hydrogen bonding (Figure 1.3). These polymers are alternately deposited on a 
sacrificial template (usually silica or CaCO3) which is subsequently dissolved to obtain 
a polymeric hollow sphere.21 LbL capsules made of poly(methacrylic acid) (PMA) are 
biodegradable, nontoxic and semipermeable, thus appear to be well suited for 
biomedical applications. However, these capsules lose cohesion at physiological pH. 
This drawback can be solved by crosslinking, but at the cost of the function of 
associated biomolecules.22 
In contrast, amphiphilic block-copolymers lend themselves to forming 
polymeric vesicles (polymersomes) via self-assembly, which feature enhanced 
mechanical properties while avoiding crosslinking associated drawbacks (Figure 
1.3). The wide variety of hydrophilic and hydrophobic blocks enable fine tuning of 
polymersomes properties, thus achieving desired responsiveness, permeability, 
functionalization, and accommodation of biomolecules. When built from the 
appropriate block-copolymers, polymersomes are also non-toxic, thus appear to be 
ideal candidates to develop polymer-based bio-hybrid compartments for biomedical 
applications. 
Figure 1.3. Schematic representation of the different types of hybrid polymer/biomolecule 
compartments (polymersomes, PICsomes, LbL capsules), showing their diversity in terms 





1.3 Polymersome formation: self-assembly of amphiphilic block 
copolymers 
1.3.1 Structure and synthesis of amphiphilic block copolymers 
Amphiphilic block-copolymers can consist of two (AB), three (ABA/ABC) or even more 
(ABABAB…) blocks with one being hydrophilic (A and C) and the other one being 
hydrophobic (B). Either the two polymeric blocks are prepared separately and then 
connected by covalent bonding (e.g. by a click reaction) or the first block is 
functionalized after its polymerization to become a “macroinitiator”.23 The first block 
can thus be extended just by addition of the second type of monomer.  
Commonly used polymerizations include controlled radical polymerization (e.g. 
ATRP, RAFT) and ionic (ring-opening) polymerizations and their combinations.24 
Popular hydrophilic blocks include PMOXA, PEG, PAA and PIAT and examples for 
hydrophobic blocks comprise PDMS, PS, PMA, PB, PCL, PHPMA, or PNIPAM. In case 
one of the blocks used responds to a certain chemical or physical stimulus, the 
resulting vesicles bear a high potential for applications in triggered drug release or the 
field of sensors. Thus, the properties of the vesicles can be fine-tuned by the careful 
selection of the hydrophobic and hydrophilic polymer blocks.  
 
1.3.2 Membranes made of block copolymers 
Different types of block copolymers can organize into different types of membranes. 
For example, diblock copolymers (AB) arrange to form an AB-BA bilayer where the 
hydrophobic blocks face each other in the core of the membrane and the hydrophilic 
ones are directied to the aqueous solution outside and inside the vesicle (Figure 1.4 
A). Such a polymeric architecture closely resembles membranes of biological cells and 
thus, with appropriate block-length can accommodate membrane protein insertion. 
Membrane proteins can also insert into triblock copolymer membranes, which can be 
monolayer (ABA) structures as well as bilayers with a U type configuration of the 
polymer (Figure 1.4 A).25 In case of immiscible hydrophilic blocks (A and C), they 
can form domains within the vesicle’s membrane.26 Moreover, a selective orientation 
of the longer block towards the outside and the shorter one towards the vesicle’s 





copolymers.27 Such asymmetric membranes can favor the insertion of a membrane 
protein in a specific orientation. Depending on the molecular weight of the block-
copolymers, the membrane thickness of vesicles can vary in the range of 5-30 nm.9 
The glass-transition temperature Tg of the polymers also needs to be taken into 
account, especially when aiming for bio-hybrid compartments with membrane 
insertion or proteins, since Tg determines the flexibility of the membrane as function 
of temperature.28 The properties (permeability, mechanical stability, ability to insert 
membrane proteins) of the resulting polymersomes are directly influenced by the 
characteristics (type and length) of building blocks used to form the polymeric 
membrane, which makes up the scaffold for the final bio-hybrid compartment. As an 
example, polymersomes made of PDMS-PMOXA are typically impermeable, even for 
small molecules whereas vesicles assembled from PS-PIAT are semipermeable.29 
 
 
1.3.3 Parameters governing self-assembly 
The self-organization of amphiphilic block copolymers does not necessarily result in 
vesicular structures but in spherical, cylindrical, gyroidal or lamellar ones instead.23 
The influence of the copolymer design on the morphology of self-assembled structures 
is described by the packing parameter p. It is defined as p=v/aOlc with v = volume of 
the hydrophobic part, aO = contact area of the head group and lc length of the 
hydrophobic part.30,31 (Figure 1.4B) Vesicles are formed for 1/2 ≤ p ≤ 1, when p ≤ 1/3 
is typical of spherical micelles and 1/3 < p ≤ 1/2 corresponds to cylindrical micelles.31,32 
Figure 1.4. (A) Schematic representation of different membrane architectures resulting 
from different copolymer structures. (B) Influence of the copolymer’s f-ratio on the 





The ratio of the hydrophilic to hydrophobic blocks determines to a great extent the 
curvature of the membrane structures formed during self-assembly (Figure 
1.4B).30,31,33 The f-ratio, i.e. the ratio of the hydrophilic block’s molecular weight (MW) 
to the total MW of the block-copolymer, characterizes the propensity for a specific 
structure: vesicular structures are generally favored at f-ratios of 35 ± 10%33 although 
the specific copolymer also pays a role.34,35 Higher f-ratios lead to a higher membrane 
curvature and thus favor the formation of spherical micelles. Finally, the greater 
stability of assemblies made of block-copolymers compared to their lipidic 
counterparts is illustrated by the critical aggregation concentration (CAC), which 
represents the concentration of amphiphilic molecules required to start forming a 
colloidal system: CAC is 10’000-fold higher for lipids than for block copolymers.36 
Besides the chemical composition, the MW and the dispersity of the block-copolymer, 
the self-assembly is influenced as well by several external factors like the solvents used, 
the concentration, the presence of acids, bases or salts, and the method used for the 
preparation of the vesicles.30  
 
1.3.4 Formation techniques 
Several techniques are used to support the self-assembly of block copolymers into 
vesicles. Direct dissolution methods where block-copolymers are dissolved in water or 
aqueous buffer usually result in the formation or large vesicles with very high 
dispersity. Film rehydration methods expose an anhydrous copolymer film to a 
rehydration medium (usually water or an aqueous buffer). Usually combined with 
stirring, it induces film swelling and self-assembly into vesicular structures. The 
mutual diffusion between the rehydration solvent and the polymer film determines the 
formation of the polymersomes: high concentration gradients result in the formation 
of nano-sized vesicles while mild diffusion conditions lead to micro-sized vesicles.30,37 
If micro-sized vesicles (giant unilamellar vesicles, GUVs) are desired, the rehydration 
can also be supported by an oscillating electric field (electroformation). As film 
rehydration does not result in homogeneous size distributions, nano-sized 
polymersomes can be extruded through a membrane with defined nanopores in order 
to narrow the size distribution to smaller sizes. Film rehydration is particularly 
applicable to membrane protein insertion, as it enables the incorporation of 





interest in the usually aqueous rehydration solution. In the same manner, using a 
rehydration buffer containing hydrophilic molecules, e.g., proteins or enzymes, results 
in the encapsulation of these molecules within the polymersome’s cavity. As the 
organic solvents are evaporated prior to the addition of the aqueous rehydration 
solution (containing the active molecules), the film rehydration technique is of 
particular interest for the incorporation of sensitive biomolecules within 
polymersomes.38  
Microfluidic tools are needed to achieve homogenous size distributions of 
micro-sized polymersomes. The copolymers are dissolved in the oil phase of 
water/oil/water double emulsions produced by the microfluidic device. Removal of 
the oil phase results in the formation of highly monodisperse GUVs. W/o/w double 
emulsions are also used in emulsion centrifugation which is the phase transfer of 
emulsion droplets over an interface. This method has been used for the preparation of 
lipid-copolymer hybrid GUVs39 and for the encapsulation of liposomes into GUVs.40 
Microfluidics enable the insertion of membrane proteins and encapsulation of 
biomolecules within GUVs, with the advantage of controlling the concentration of 
encapsulated compounds.17 However, the incorporation of sensitive biomolecules and 
the formation of nano-sized polymersomes are yet to be achieved, which limits the use 
of microfluidics to develop bio-hybrid compartments for biomedical applications.  
Other methods involving the slow exposure of a copolymer solution in an 
organic solvent to an aqueous environment (solvent switch, cosolvent and water 
addition/solvent evaporation methods), also induce self-assembly into polymersomes 
or GUVs. The copolymer solution can be either added to water or water can be added 
slowly to the organic copolymer solution. Subsequently, the organic solvent is either 
removed by evaporation or by dialysis against water. The presence of the organic 
solvent during self-assembly limits the application of these methods for bio-hybrid 
vesicle production as it might harm the functionality of the biomolecules. More 
detailed information on the preparation methods and their comparison are provided 






1.4 Bio-hybrid polymersomes as attractive platform for 
biomedical applications 
1.4.1 Surface functionalization of polymersomes with biomolecules 
Following the formation of the polymeric nanocompartments, the surface of 
polymersomes can be decorated via the chemical ligation of biomolecules. Such 
modifications have been widely exploited in medical applications, especially for 
targeting and drug delivery purposes.11,41–45 Cell specific targeting ligands like 
antibodies can be used to surface-functionalize polymersomes, in order to combine the 
robustness and loading capacity of the polymeric compartments with the high binding 
affinity of antibodies.41,46 However, antibodies are expensive to produce, large in size 
and often immunogenic which calls for alternatives. Targeting and cell penetrating 
peptides, less expensive and smaller than antibodies, have been widely exploited to 
target polymersomes to locations of interest within cells or living organisms. For 
example, cyclic (RGD and NGQ)11,12,42,47, pH sensitive fusogenic (GALA)11 and other 
targeting (GE11, LinTT1, ApoE, Tet-1, NLS)43,44,48–51 peptides have been mainly used 
to deliver smart polymer vehicles to specific cells or organelles and/or to improve their 
tumour penetration for therapeutic or diagnostic applications. Another approach 
consist in the coupling of peptides to the block copolymers prior to vesicle formation 
via mixing of the non-functionalized polymer with a peptide-functionalized 
counterpart that self-assemble together to form peptide-functionalized 
polymersomes.12,47–50 This approach enables the simultaneous use of different types of 
polymer, e.g., by mixing a triblock co-polymer with a peptide-functionalized diblock 
copolymer. However, several features like the use of polymers with matching lengths 
of hydrophilic and hydrophobic parts, are crucial in order to achieve their co-self-
assembly into polymersomes.12 To potentiate the targeting/cell penetrating effect, it is 
also common to use a peptide-functionalized co-polymer with a slightly longer 
hydrophilic block to enhance the exposure of the peptide.50 
Just like their shorter counterparts, proteins like transferrin can be covalently 
attached to the surface of preformed polymersomes for targeting purposes.44,52,53 For 
other applications such as sensors and regulating systems, the surface of 
polymersomes can be enriched with proteins via electrostatic interactions, and 
subsequently immobilizied using photo-crosslinking.54 This way, surface immobilized 





their compound of affinity from the external environment, as exemplified by an anti-
diabetes system.54 Furthermore, surface immobilized proteins that are fluorescently 
labelled are exploited as tags to monitor processes occurring within the membrane. 
For example the membrane insertion of a non-fluorescent anchor of interest can be 
detected by linking fluorescent GFP to it.55 
Nucleic acid-based compounds can also decorate the surface of polymersomes 
for targeting applications. Of particular interest are aptamers which are DNA or RNA 
single strands with high binding affinity to specific targets, e.g., certain types of cancer 
cells.56,57 For other applications, the specificity of the hybridization of single-stranded 
DNA (ssDNA) to their complementary strands was exploited to selectively connect 
distinct polymersomes that are surface-functionalized with complementary ssDNA. 
This approach enables different spatial organizations of polymersomes into clusters 




Besides applications such as sensing, attachment or spatial organization, the 
main objective of surface functionalization of polymersomes is targeting, which 
explains the recurrence of selected biomolecules (antibody, peptides, DNA) able to 
direct polymersomes to a location of choice. However, targeting of polymersomes is 
Figure 1.5. (A) Cryo transmission electron micrograph of DNA functionalized 
polymersome clusters showing clearly the morphology, the membrane thickness 
and the gap created by the attached DNA strands. (B) Normalized fluorescence 
correlation spectroscopy autocorrelation curve of polymersomes functionalized 
with ssDNA and the hybridized fluorescently labelled complementary strand (dark 
yellow, red fit) and the free fluorescently labelled ssDNA (blue, red fit). Reprinted 





only of interest if they deliver a specific function, which is usually obtained by 
encapsulation of specific compounds or potent biomolecules inside their cavity. 
 
1.4.2 Encapsulation of biomolecules within the polymersome cavity  
Polymersomes are appealing carriers for hydrophilic compounds and biomolecules, 
especially for catalytic and sensitive molecules like enzymes, as they offer a confined 
environment inside their aqueous cavity and are thus able to protect the payload from 
the external milieu. Polymeric vesicles encapsulating nucleic acid cargos (plasmid 
DNA, siRNA) offer protection from nuclease degradation, which makes them strong 
candidates for non-viral, potentially safer, gene delivery systems.46,59,60 Slightly 
positively charged polymers can support the challenging encapsulation of large nucleic 
acids like plasmids or entire genes, by binding the negatively charged DNA via 
electrostatic forces.59,60 However, such interactions can also destabilize the 
polymersomes or prevent their self- assembly. Thus, the length of the polymer block 
containing protonatable groups as well as the pH of the rehydration solution have to 
be carefully optimized to render DNA encapsulation compatible with self-assembly 
conditions.59,60 
Enzymes can be encapsulated inside the polymersomes’ cavity to develop 
catalytic nanocompartments, often called nanoreactors, able to produce or degrade 
compounds of interest.61 Depending on the loaded enzymes, such bio-hybrid systems 
aim at different applications, e.g., as antioxidant by using superoxide dismutase or 
haemoglobin.13,62 To cumulate several activities, two kinds of catalytic compartments 
(encapsulating different enzymes, e.g. uricase and horseradish peroxidase, HRP) that 
work in tandem have been used, for example to achieve simultaneous detoxification 
and uric acid degradation for therapeutic applications (Figure 1.6A).63 Also, such 
systems are interesting models to investigate the effects of distance on the overall 
cascade reaction efficiency as they mimic the communication within bioassemblies 
like cells and organelles (Figure 1.6B).63 Indeed, the ratio between the mean 
intercompartment distance and the diameter of the compartments is about 10, which 
reflects the order of magnitude of the ratio between cell-cell communication distance 
(for cells with 1 µm distance typical for autocrine signaling). The 
compartmentalization of enzymatic cascade reactions is of particular interest as the 





therapeutic applications, catalytic polymersomes are also used as model for artificial 
organelles (e.g. chloroplast,64 peroxisome65), and as building blocks of antimicrobial 
surfaces66 or biosensors.67 
 
 
   
 
The segregation of enzymes within the polymersome cavity primarily aims at 
shielding them from proteolytic degradation. However, it is essential to maintain the 
exchange between the encapsulated enzymes and the external environment in order 
to obtain catalytic activity of nanocompartment. The majority of the polymersomes, 
e.g., assembled from PS-PIAT68 or PGG14, are inherently permeable to small molecules 
and thus permit a supply of substrate for the encapsulated enzyme and the exit of the 
resulting product from the compartment. The permeability of polymersomes can be 
varied depending on different conditions, for example by inserting responsive 
compounds in the polymeric membrane or by using responsive polymers like 
PNIMAM that is temperature-responsive. In contrast, polymersomes made of PDMS-
PMOXA block copolymers are impermeable to small molecules. Selective permeability 
has been achieved via incorporation of pores or channels in the polymeric membrane 
(see next section).69 To study the permeabilization of the vesicles as well as the 
diffusion of compounds across their polymeric membrane, catalytic compartments 
encapsulating stable enzymes has been used for basic research rather than for 
Figure 1.6. (A) Scheme of the two catatylic compartments working in tandem. (B) 
Conversion of substrate Amplex Red by cascade reaction inside the catalytic 
compartments in tandem representing the cascade reaction efficiency, at different mean 





biomedical applications: model enzymes as HRP and glucose oxidase (GOx) benefit 
from the well-established, accessible and convenient monitoring of their reaction 
kinetics, which makes these enzymes suitable for the development of artificial cells70, 
models of molecular crowding71 or for studying enzyme positioning within the 
polymersomes.68 These model enzymes demonstrated that enzyme confinement 
coupled with a crowded milieu inside polymersomes affects the enzyme kinetics by 
lowering the Michaelis–Menten constant (Km) compared to non-encapsulated 
enzymes (Figure 1.7).71 The co-encapsulation of a substance simulating molecular 
crowding such as PEG with HRP results in even lower Km (Figure 1.7).71 When co-
encapsulated with their substrate, the decrease of Km for encapsulated enzymes leads 
to a greater enzyme-substrate affinity because of the molecular confinement inside the 
compartment that increases the collision frequencies between the reagents.71 
In a different system where enzymes are encapsulated inside impermeable 
PMOXA-PDMS-PMOXA polymersomes and the substrate has to diffuse through the 
pore to reach the enzymes rather than being co-encapsulated, the diffusion effect is 
the limiting factor of enzyme efficiency. In fact, if the substrate readily encounters the 
enzyme once in the compartment (low Km), the slower efflux of substrate towards the 
cavity of polymersomes hinders the enzyme activity, according to the decrease of 
catalytic efficiency (kcat/Km).63 These parameters (Km, kcat/Km, viscosity) are key 
factors that need to be optimized when developing efficient catalytic 
nanocompartments.71 However, the Michaelis-Menten model cannot be applied to all 
catalytic nanocompartments systems including catalytic polymersomes working in 
tandem to support cascade reactions or enzymes with complicated kinetics 
monitoring. 
From therapeutic compounds to catalytic biomolecules (enzymes), 
encapsulated cargos mainly determine the application of the bio-hybrid 
nanocompartment. However, the encapsulated payloads can only fulfil their 
active/therapeutic role in response to environmental conditions, which is usually 








1.4.3 Membrane functionalization of polymersomes with biomolecules  
Biomolecules containing a hydrophobic domain can be inserted into the polymeric 
membrane to add new features such as stimuli-responsiveness, to the bio-hybrid 
nanocompartments. During self-assembly of polymersomes, peptides can be inserted 
into the polymeric membrane, to achieve ion-selective membrane permeability72 or 
proteinase responsiveness with disruption of the peptide/polymer hybrid assembly.73 
Some peptides, typically derived from the transmembrane domains of membrane 
proteins from viral, yeast or bacteriophage sources, also spontaneously insert into the 
polymeric membrane of preformed polymersomes.55 Their insertion appears to be a 
concentration-dependent process governed by hydrophobic driving forces. Such ease 
of insertion has been exploited for the functionalization of polymersomes with other 
molecules, via the use of peptide/other molecule conjugates that can insert without 
destabilizing or rupturing the polymersome membranes.55 
Proteins have been used as a major structural component of bio-hybrid 
polymersomes, e.g., assemblies of conjugated hydrophilic human serum albumin 
(BSA) and a hydrophobic polymer block show great potential as drug delivery 
vehicles.74,75 Asymmetric conjugates made of ABC triblock copolymers containing 
Figure 1.7. Michaelis-Menten constant of HRP (free 
in solution and encapsulated in polymersomes) in 
presence of different concentrations of PEG. Km 
decreases with increasing concentrations of PEG. 





either HRP or myoglobin, have been shown to form vesicles but also other 
nanoassemblies like micelles or rods.76 However, only a few examples of such protein-
polymer conjugates have been reported to form the desired nanoassemblies as the 
inherent complexity of these systems impedes the control over their architecture. 
 Membrane proteins have been reconstituted in polymeric membranes, to 
permeabilize otherwise impermeable polymersomes via the membrane insertion of 
protein pores like Outer membrane protein F (OmpF). This porin has a molecular 
weight cut-off of 600 Da which permits the passage of small molecules into and from 
the inner space of polymersomes while retaining bigger encapsulated macromolecules 
like enzymes inside.71 OmpF can be chemically modified prior to membrane insertion 
to obtain pores that open in response to a pH change in the environment77 or function 
as biovalves with a controllable opening and closing of the pore78. The successful 
incorporation of membrane proteins can be achieved even though polymeric 
membranes are thicker than cellular membranes. Remarkably, the hydrophobic part 
of polymeric membranes is thicker than the hydrophobic domain of the membrane 
proteins, which suggests a conformational adaptation between the polymer and the 
protein to overcome the hydrophobic mismatch (Figure 1.8).8 However, this 
phenomenon of adaption requires specific properties of the polymeric membrane: a 
high flexibility of block-copolymers is essential to achieve membrane fluidity that is 
similar to natural phospholipidic bilayers.8 Moreover, the hydrophobic mismatch 
between the membrane thickness and the size of the protein also influences the 
insertion process as it should range from 3.5 to 5 times to achieve a successful protein 
reconstitution (Figure 1.8). Finally, block-copolymers with high polydispersity index 
(PDI) also favor protein insertion as they enhance the ability of the polymer chains to 
adapt to the dimensions of protein.8 ABC triblock copolymers have been used to mimic 
the asymmetry of biological membranes, which is conducive to a preferential 
orientation of the inserted protein,79 e.g., to allow for a directional transport across the 
membrane or to control which domains of the protein are exposed towards the cavity 
or the surface of vesicles. Recent advances in polymer chemistry moved these synthetic 
membranes closer to their biological inspiration, thus allowing the successful insertion 
of a number of proteins (α-hemolysin,80 Bacteriorhodopsin81 or AquaporinZ82) into 
polymeric membranes. However, the reconstitution of membrane proteins in polymer 





adapted surfactant and pH conditions and strategies to deal with the hydrophobic size 
mismatch between the protein and the synthetic membrane.83  
Carbohydrates have also been inserted in polymeric membrane, in view of their 
manifold roles in cellular process, notably in cell-cell and cell-matrix communication. 
The resulting bio-hybrids have been exploited for applications like cell-surface 
recognition and cell signalling.14,84–86 Bio-hybrid vesicles made of block-copolymers 
containing sugar moieties have been targeted to other applications like detection of 











Figure 1.8. Schematic representation of the structural change of the polymeric 
membrane required to compensate the hydrophobic mismatch between the 
hydrophobic membrane thickness and the hydrophobic height of the membrane 






1.4.4 Polymer-lipid hybrid vesicles 
Phospholipids combined with block copolymers have gained interest for the 
formation of hybrid vesicles with membrane properties closer to biological ones, which 
have been studied in the context of interaction with cells.88–90 Both types of 
macromolecules can also form hybrid vesicles when blended, bringing together the 
biocompatibility and softness of liposomes and robustness and chemical versatility of 
polymersomes. The successful assembly of these hybrids closely depends on the 
amphiphilic building blocks: molar fraction, molecular weight and block size have to 
be optimized.90–93 These bio-hybrid vesicles exhibit higher permeability compared to 
polymersomes and liposomes, which has been further enhanced by the insertion of 
ionophores or ion channels94  However, the biggest potential of lipid/polymer hybrid 
vesicles lies in facilitating reconstitution of membrane proteins as they form a durable 
environment that lowers the initial enzyme activity but enables a significant extension 
of the functional lifetime of the protein compared to its reconstitution in liposomes.95 
These hybrids possess a great potential for drug delivery due to their low toxicity and 
efficacy of payload loading and release that can be modulated by the polymer/lipid 
ratio.93,96,97 However, the insertion of a lipid into the polymeric membrane can be a 
drawback in case of further surface functionalization of the hybrid vesicle: the addition 
of lipids is diluting the density of polymer brushes on the vesicle’s surface that are 
obstructing targeting ligands due to steric effects.  
Taking together, the incorporation of biomolecules in the polymersome 
membranes mainly enhances the tunability of the membrane, especially permeability 
and responsiveness. However, the countless combination possibilities of producing 
bio-hybrid assemblies are greatly limited by the challenges associated with the 
complex accommodation between polymers and biomolecules. 
 
1.4.5 Principal bio-medical applications of bio-hybrid polymersomes 
As illustrated in Table 1, most polymer-based bio-hybrid nanocompartments are 
developed as study models, for example to gain insight on protein reconstitution in 
polymeric membrane81,83,95 or to mimic natural organelles58,64,65,94. When it comes to 
therapeutic applications, the vast majority of these bio-hybrids are used as drug 





drugs as 5-fluorouracil89 or doxorubicin49, is easily achieved as these compounds are 
usually small and relatively stable which facilitate the encapsulation process. In such 
drug delivery systems, the combined biomolecules are mostly peptides that serve to 
confer targeting properties upon the therapeutic vehicle. More rarely, instead of drugs, 
similar systems are employed to deliver therapeutic biomolecules such as enzymes50 
or nucleic acids59,60, for targeted protein therapy and gene therapy, respectively. For 
example, the toxic enzyme saporin can be delivered to cancer cells to inactivate 
ribosomes, thus preventing protein synthesis leading to cell death.50 However, for such 
delivery applications, the release of the encapsulated drug/therapeutic biomolecule is 
necessary for a therapeutic effect. In most instances, release has been achieved by 
using pH or temperature responsive polymers.88,98   
Other therapeutic applications like detoxification, e.g., of ROS13,62 or uric acid63, 
usually implies the encapsulation of adequate enzymes capable to degrade the harmful 
compounds. However, in such cases, the release of the enzyme is better avoided: it is 
preferable to keep the enzymes encapsulated to preserve their activity, e.g., by 
shielding them from proteolytic degradation. Given appropriate permeabilization of 
the polymeric membrane, the harmful compounds can enter the polymersome’s cavity 
where they are degraded by the enzyme. On the other hand, larger molecules as 
proteases, are excluded from the therapeutic compartment. Similar systems have been 
used for enzyme prodrug therapy, where encapsulated enzymes, e.g., β-galactosidase 
(β-gal), generate active chemotherapeutics from prodrugs.14 
In contrast to direct therapeutic purposes, some bio-hybrid systems aim at 
other biomedical application like imaging. For example, the in vivo targeting and 
imaging of bone metastases have been achieved via encapsulation of MRI agents and 
surface functionalization of polymersomes with antibodies.41 Thus, the display and 
composition of bio-hybrid systems is directly correlated to their applications purposes. 
Because bio-hybrid systems able to present dual or even multiple activities involve 
infinitely more complex designs, they are by far more challenging. For example, anti-
tumor applications achieved by drug delivery and in situ ROS production have been 
explored by bio-hybrid polymersomes containing drugs (camptothecin) in their 
membrane and glucose oxidase (GOx) inside their cavity.99 Triggered by the acid 
environment of the tumor, the polymersome membrane became permeable to glucose 
which was subsequently oxidized by encapsulated GOx with a concomitant production 
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1.4.6 Limitations and possible directions of improvement 
Catalytic bio-hybrids involving the encapsulation of enzymes have the potential to 
improve and extend the bio-medical applications of nano-sized compartments. For 
example, such systems allow for longer circulation times of the enzymes and thus 
prolonged activity, while reducing off-target toxicity due to on-site production of 
drugs.106,107 Considering the vast range of reactions catalysed by enzymes, such 
systems could be applied to develop novel pro-drug therapies and go even further to 





However, there is a clear gap between bio-hybrid systems used as models, 
which depending on the study involve intricate architectures, and bio-hybrids tailored 
to specific bio-medical applications that usually consist of simpler 
polymer/biomolecules combinations. To explore the potency of complex model bio-
hybrid systems, the same stable and easy to characterise model enzymes (HRP, β-gal, 
GOx) are often employed because they are rather stable and easy to 
characterise.17,69,77,78 Even if these model enzymes were suitable for therapeutic 
purposes, the range of applications is very limited as the variety of model enzymes is 
restricted.14,63,99 In addition, the transfer from model system to applicability is rarely 
straightforward: a bio-hybrid system that has been developed to accommodate stable 
model enzymes is not readily adaptable to other enzymes offering greater potential for 
bio-medical applications. 
Difficulties arising from the production/supply of enzymes of interest (low 
concentration, purity, high costs), as well as from merging enzyme’ requirements 
(temperature, pH, buffer) with polymersome formation/functionalization conditions 
have to be overcome to build functional systems. To tackle these issues, different 
strategies could be pursued like, 1) using polymers that easily self-assemble under a 
broad range of conditions and at the same time enable the incorporation of membrane 
proteins, 2) selecting enzymes (where a good balance between desired activity, 
stability, cofactors, size, hydrophilicity and encapsulation efficiency is feasible), 3) 
choosing efficient reactions/appropriate biomolecules for the functionalization of the 
polymersomes and 4) segregating different compounds of interest in different 
compartments to meet their respective needs and preserve their 












2. Aim of the thesis 
 
The aim of this thesis it to implement the above-mentioned strategies, in the 
development of polymersome-based enzyme encapsulating compartments 
as stepping stones towards novel bio-medical applications. The different 
systems, presented below are all built of di-block PDMS-PMOXA copolymers, while the 
encapsulated enzymes and other associated biomolecules vary depending on the target 
application. 
To provide a platform for the development of dual-function bio-hybrid 
systems, e.g., for theranostic applications, we investigated using super-
assemblies of nano-size compartments where distinct active compounds are 
segregated (Chapter 3). To overcome one of the preeminent constraints in achieving 
dual-function bio-hybrid systems, i.e., the combination of different active compounds 
without sacrificing their activity, we designed a system comprising two different type of 
polymersomes: one bearing an imaging function via the encapsulation of fluorescent dye 
and the other encapsulating recombinant human enzyme Dopa decarboxylase (DDC) to 
produce dopamine as therapeutic compound. To assure co-localisation of both 
polymersomes, so both functions in close proximity, and at the same time procure 
specific cell attachment properties, we explored the surface functionalization of 
individual polymersomes with complementary DNA strands. To provide evidence of the 
applicability of such a system, e.g., for the treatment of atherosclerosis, the stability of 
the assembly as well as the therapeutic and imaging functions have been assessed in cell 
cultures. Finally, to position this novel system as platform for the developing of future 
dual-functional bio-hybrid systems, the modularity of the polymersome clusters was 
evaluated.  
To pave the way for a novel kind of pre-clinical imaging application, we 
developed a polymersome-based bioluminescent system producing a strong 
and long-lasing light signal (Chapter 4). We exploited bioluminescence to develop 
a novel imaging system based on nanocompartments to ultimately have available a safer, 
more convenient and more affordable alternative to nuclear imaging and MRI. 





polymersomes that have been permeabilized via incorporation of OmpF. We investigated 
the effect of substrate diffusion through OmpF on the enzyme’s kinetics and the resulting 
modulation of the light signal. To gain insight into the applicability of this system, we 
investigated its activity, cytotoxicity and stability in a cellular environment and carried 
out preliminary in vivo studies using a mouse model. 
To offer a cell photoprotective system that sidesteps typical drawbacks 
associated with melanin/Polydopamine nanoparticles, we developed 
melanosome mimics (Chapter 5). Melanin nanoparticles and especially their 
synthetic counterparts made of polydopamine have been extensively used for their great 
light-absorption properties. However, their compromised long-term colloidal stability 
and propensity for cytotoxicity restrict their biomedical applications. Inspired by nature, 
i.e., by native melanosomes, we examined the behavior of confined 
melanin/polydopamine by means of polymersomes encapsulating Tyrosinase, a key 
enzyme in melanogenesis, together with melanin/polydopamine precursors L-DOPA or 
Dopamine, respectively. To assess the applicability of this melanosome mimics, we 
monitored their colloidal stability upon long-term storage, cytotoxicity, as well as their 






















3. Polymersome clusters as 
nanotheranostic platform 
 
This chapter focus on the development of a nanocompartment-based theranostic 
system, where nanomaterials and biologically active compounds are merged to 
achieve diagnosis and treatment at the same time.  The current dual-functional 
nanosystems, e.g., targeted at theranostics, have serious limitations, mainly because 
there is often a mismatch between the physical properties of the selected 
nanomaterials and their ease of functionalization, loading ability or overall 
compatibility with bioactive molecules. Herein we propose a new type of 
nanotheranostic system based on nanocompartment clusters composed of two 
different types of polymersomes linked together by DNA. Careful design and 
procedure optimization were investigated to obtain clusters segregating human 
Dopa decarboxylase (DDC) as the therapeutic enzyme and fluorescent probes for the 
detection unit in distinct but colocalized nanocompartments. This dual-functionality 
polymersome cluster architecture provides a novel type of two-compartment 
nanotheranostic platform that is expected to provide the basis of a new treatment 
strategy for atherosclerosis. Also, this system is expected to expand versatility and 
diversify the types of utilizable active molecules, and thus by extension expand the 
breadth of attainable applications via dual-functional systems.  
 
___________________________________________   
Parts of this chapter have been published and reprinted with permission from108,109 
C. E. Meyer, J. Liu, I. Craciun, D. Wu, H. Wang, M. Xie, M. Fussenegger, C. G. 
Palivan, Segregated nanocompartments containing therapeuthic enzymes and 
imaging compounds within DNA-zipped polymersome clusters for advanced 
nanotheranostic platform, Small, 2020, 16, 1906492 
C. E. Meyer, C-A Schoenenberger, J. Liu, I. Craciun, C. G. Palivan, DNA-tethered 







Theranostic approaches provide improved medical solutions by associating therapy 
with diagnostics, thereby avoiding multi-step procedures and reducing delays in 
treatment, which may be particularly crucial in the case of rapidly evolving diseases.  
The therapeutic part of theranostic systems is usually achieved via release of bioactive 
compounds, hyperthermia or ROS production, while the diagnosis part mostly 
involves imaging methods like MRI, fluorescence or ultrasound.110 Theranostic 
systems are often based on nanomaterials whose small size and interesting intrinsic 
properties make them particularly suited for such dual applications. For example, 
inorganic nanoparticles like quantum dots possess the unique advantage of being 
intrinsic imaging agents but their potential toxicity limits application.110,111 On the 
other hand, lipid- or polymer-based micelles are potent support materials as they are 
non-toxic and can integrate hydrophobic therapeutic/imaging agents within their 
hydrophobic core.110,112 However, increasing the range of applications crucially 
depends on improving the loading capacity for hydrophilic active compounds which 
cannot be achieved by using micelles. Of particular interest are soft 
nanocompartments, i.e. liposomes and polymersomes, as they consist of an 
amphiphilic membrane enclosing an aqueous cavity and therefore allow for 
integrating hydrophobic compounds within their membrane and loading their cavity 
with hydrophilic compounds.1,113,114 In addition, the external surface of 
nanocompartments can be functionalized to gain targeting properties, especially in the 
case of polymersomes as they benefit from the sheer endless chemical versatility of 
polymers.1 As polymersomes have an increased mechanical stability compared to 
liposomes, they appear to be ideal materials for building a non-toxic nanotheranostic 
platform, adaptable to different applications.1,113     
To date, nanotheranostics based on soft nanocompartments mainly consist of 
single-assembly architectures containing both therapeutic (e.g., drugs, 
photosensitizers, enzymes) and imaging compounds (e.g., iron oxide nanoparticles, 
radioisotopes, fluorescent dyes).10 However, co-encapsulation can be detrimental for 
sensitive compounds or negatively affect the encapsulation efficiency of active agents. 
These serious drawbacks can be overcome by another type of nanotheranostic 





that each are equipped with either the therapeutic or the imaging function. However, 
most super-assemblies are composed of inorganic nanoparticles and/or held together 
by weak, non-covalent interactions that compromise their efficacy, especially under 
physiological conditions where dissociation of the assembly is likely to occur.115–117   
To overcome such constraints, we developed a super-assembly composed of two 
different types of polymersomes, one bearing the therapeutic function while the other 
one enables imaging, tethered together by hybridization of complementary DNA 
strands exposed on the respective surfaces (Figure 3.1).58,108 In addition, the ssDNA 
not involved in tethering served to promote attachment to cells expressing scavenger 
receptors, e.g., epithelial cells.118 In view of the encapsulated enzyme (Dopa 
Decarboxylase, DCC) segregated within the therapeutic polymersomes, our system is 
geared towards applications in the treatment of atherosclerosis in that polymersome 
clusters could attach to atherosclerotic lesions, produce and deliver on-site a 
therapeutic compound (dopamine), while at the same time, the imaging compartment 
filled with fluorescent dye (Dy-633) serves to follow the lesions’ dynamics by the 
imaging modality.108 The communication between the external environment and the 
polymersome cavity where enzymes were located, was accomplished by 
permeabilization of the polymer membrane via incorporation of pore forming proteins 
(Outer membrane protein F, OmpF).8,61  
The potency of the theranostic clusters was evaluated with the cell line 
HEKREWARD, which is specifically engineered to express human dopamine receptor 1 
(DRD1)119 and thus is able to respond to dopamine enzymatically produced in the 
catalytic nanocompartment. The therapeutic activity of the DNA-linked polymersome 
clusters was determined by evaluating the concentration of the reporter, human 
secreted embryonic alkaline phosphatase (SEAP), produced by HEKREWARD cells in the 
presence of dopamine, while their imaging function was established by visualizing 
their localization and interaction with the cell surface. 
The unique advantage of our DNA-linked polymersome clusters over other 
currently available theranostic systems resides in the segregated location of the 
imaging and catalytic compounds, which allows them to act independently, without 
interference that might compromise their specific functionality. As our strategy is 
based on a modular design, it should be straightforward to expand it from the example 





functional components, e.g., biomolecules, within the segregated compartments, and 




Figure 3.1. Schematic illustration of cell attachment of DNA-zipped theranostic 
polymersome clusters composed of two distinct compartments: therapeutic DDC-Ncomp 
and imaging Dye-Ncomp. While Dye-Ncomp contains fluorescent DY-633 dye, DDC-
Ncomp contains DDC, which catalyzes the conversion of L-DOPA into dopamine. This, in 
turn, triggers gene expression in cells via activation of dopamine receptors D1 (DRD1) 
resulting in the production of SEAP reporter enzyme. The nanotheranostic platform 
attaches to the surface of epithelial cells via interaction between DNA strands and 






3.2 Design of the nanotheranostic platform 
3.2.1 Development strategy of DNA-linked polymersome clusters 
Theranostic clusters are formed by self-organization of two types of 
nanocompartments: the therapeutic polymeric compartment that contains the 
catalytically active species, and the imaging polymeric compartment that allows the 
detection and tracking of the whole clusters (Figure 3.1). DNA hybridization was used 
as the driving force to control the construction of nanocompartment clusters with sub-
micrometer size.58 The therapeutic compartment was functionalized with one type of 
ssDNA (ssDNAa), while the imaging compartment bears the complementary ssDNAb 
at its surface (see Table 3 in annex for the details of ssDNA sequences). In order to 
modulate the DNA attachment to the polymersomes, we also used variants of these 
ssDNA sequences (called spacer-ssDNAa and spacer-ssDNAb), which contain an 
additional noncomplementary DNA linker acting as a spacer between the surface of 
the polymersomes and the complementary DNA sequence. We compared clusters 
made with ssDNA or spacer-ssDNA and ssDNA, in order to select the most suitable 
approach to support efficient theranostic application.  
We selected amphiphilic diblock copolymers poly(dimethylsiloxane)-block-
poly(2-methyloxazoline), PDMS-PMOXA for formation of the nanocompartments, 
because copolymers with a PDMS hydrophobic domain and a PMOXA hydrophilic 
domain generate polymersomes with flexible membranes,8 increased mechanical 
stability and low toxicity, both in vitro and in vivo.120 Azide-functionalized 
poly(dimethylsiloxane)22-block-poly(2-methyloxazoline)8 (PDMS22-PMOXA8-OEG3-
N3) (Figure 10.1) was used to form polymersomes with exposed azide functional 
groups that do not interfere with other biological processes, as they are bio-
orthogonal121 and promote the attachment of ssDNA. Conjugation was carried out 
through azide–alkyne cycloaddition (SPAAC) between dibenzocyclooctyne (DBCO) 
covalently attached to the ssDNA and the azide moieties on the diblock copolymers.122 
We specifically selected short polymer blocks to generate nanocompartments with thin 
but stable membranes, in order to permit functional insertion of membrane proteins 
to support the in situ enzymatic reaction of the catalytic nanocompartment.8 
Importantly, low-molecular-weight PDMS22-PMOXA8 block copolymer is expected to 
self-assemble rapidly into vesicles, shortening the process of polymersome formation. 





into vesicles in less than 1 min when rehydrated in PBS at room temperature (Figure 
3.2). The vesicular structure of the obtained self-assembled nanocompartments was 
confirmed by a combination of transmission electron microscopy (TEM) and dynamic 
light scattering (DLS) (Figure 3.2). This ease of formation of polymersomes, 
combined with the swiftness of PDMS22-PMOXA8-OEG3-N3 copolymer formation, 
also enabled us to increase the initial concentration of copolymer to 10 mg/mL, 
resulting in a high number of polymersomes (1.3*1012 vesicles/mL as determined by 
nanoparticle tracking analysis, NTA). 
 
3.2.2 Formation of the imaging polymersome 
The imaging nanocompartment (Dye-Ncomp) consists of a polymersome loaded with 
fluorescent dye. We chose to encapsulate DY-633 into polymersomes as a model of the 
entrapment of small imaging probes in the cavity of the nanocompartments. Like most 
of the small hydrophilic molecules that have been used to develop imaging 
nanocompartments, DY-633 is chemically stable, so Dye-Ncomp was formed under 
normal conditions (room temperature, overnight stirring) by self-assembly through 
film rehydration of the PDMS22-PMOXA8-OEG3-N3 polymer (Figure 3.3A). The 
resulting imaging nanocompartments have a hydrodynamic diameter DH of 218 ± 86 
nm as measured by DLS, and their spherical shape was confirmed by TEM (Figure 
3.3B). As expected, encapsulation of the dye did not affect the self-assembly process, 
and the resultant imaging nanocompartments appeared similar to empty ones 
(Figure 3.3C). Based on these results with DY-633, the incorporation of other 
Figure 3.2. Characterization of empty polymersomes formed in less than 
1 min of film rehydration at room temperature via transmission electron 






imaging components consisting of stable small hydrophilic molecules should be 
relatively straightforward. In contrast, the development of therapeutic catalytic 
compartments is more complex, as it involves active enzymes. 
 
 
3.2.3 Optimized formation of the catalytic therapeutic polymersome 
The catalytic nanocompartment (DDC-Ncomp) consists of human DDC encapsulated 
in the inner cavity of polymersomes equipped with a channel porin, which supports in 
situ enzymatic reactions. We chose the channel porin OmpF as a biological tool for 
permabilization, as it can be inserted in the membrane of PDMS-PMOXA 
Figure 3.3. Characterization of Dye-Ncomp and empty polymersomes. (A) 
Schematic representation of the formation of Dye-Ncomp. (B) Transmission 
electron microscopy (TEM) micrograph and size obtained by dynamic light 







polymersomes and has a molecular weight cutoff of 600 Da,123 thus allowing the 
passage of small molecules such as the DDC substrate L-DOPA and product dopamine. 
Compared to other therapeutic nanocompartments reported for theranostic 
applications, which are based on the entrapment of small and stable therapeutic 
compounds,110 we aimed to develop a more versatile and dynamic system involving an 
active enzyme that produces the desired drug inside the therapeutic compartment. By 
incorporating an active enzyme, we can produce the needed therapeutic compound on 
demand at selected locations rather than having a simple one-time delivery system. 
But, like many enzymes carrying out physiological functions in the human body, DDC 
is vulnerable to degradation, and loses its activity significantly at 37 °C.124 Therefore, 
the formation of DDC-Ncomp requires a complex preparation methodology based on 
numerous optimization steps.  
To preserve DDC activity, it was crucial to conduct polymersome formation 
(self-assembly and OmpF insertion) as quickly as possible by shortening the time of 
film rehydration, since at least one day is generally required for the self-assembly of 
most amphiphilic block copolymers with high molecular weight.65,125 Our short 
PDMS22-PMOXA8-OEG3-N3 copolymer favoured the formation of polymersomes in 
less than 1 min, thus supporting a rapid generation of DDC-Ncomps (see above). The 
rapid insertion of OmpF during the such prompt formation of polymersomes was 
confirmed using model polymersomes encapsulating model enzyme horseradish 
peroxidase (HRP) that is more stable and easier to work with than DDC (Figure 
3.4).126 The production of fluorescent product (resorufin) was only observed for HRP-
loaded polymersomes formed in presence of OmpF, while no fluorescent product was 
observed when polymersomes were formed without OmpF (Figure 3.4). This 
highlights the ease with which membrane proteins can be inserted into PDMS22-







Following these preliminary optimizations using PBS and model enzyme HRP, we 
proceeded with the encapsulation of our biologically relevant enzyme DDC and 
optimized the conditions of self-assembly (composition of the rehydration solution, 
temperature and time). To prevent the degradation of DDC in solution during film 
rehydration, we added bovine serum albumin (BSA), a commonly used protein 
stabilizer.127 We also reconstituted DDC holoenzyme by adding its cofactor pyridoxal 
phosphate in the rehydration solution. The association of DDC apoenzyme with its 
cofactor generates the holoenzyme, which is less solvent-accessible, and thus more 
stable and more compact.128 As a result, the rehydration solution used to form DDC-
Ncomp contained DDC holoenzyme, remaining unbound cofactor pyridoxal 
phosphate, BSA and OmpF. The obtained DDC-Ncomp formed by rapid film 
rehydration at room temperature was a mixture of vesicles and worms (Figure 3.5A), 
probably due to the presence of a large number of molecules in the solution, slowing 
down self-assembly.129 A rehydration time of 2 h was necessary to obtain only 
vesicular-shaped DDC-Ncomp at room temperature (Figure 3.5B). To avoid the 
Figure 3.4.  Characterization of instant insertion of Outer membrane protein F (OmpF) 
in the membrane of polymersomes: A) schematic  representation of horseradish 
peroxidase (HRP encapsulated in OmpF-equipped nanocompartment, which allows the 
passage of Amplex Red through the membrane and oxidizes it to generate fluorescent 
resorufin; B) enzymatic kinetics of HRP-encapsulating nanocompartments, prepared at 
different initial concentrations of OmpF, by monitoring the fluorescent intensity of 
resorufin as a function of time; C) TEM micrographs of HRP-encapsulating 





exposure of DDC to room temperature for 2 h, which can decrease its activity, we 
investigated the possibility of forming DDC-Ncomp at low temperature (4 °C). After 2 
h of rehydration at 4 °C, we obtained a mixture of polymersomes and worms (Figure 





Figure 3.5.  Characterization of DDC-Ncomp. (A) TEM micrographs of DDC-
Ncomp instantly formed at RT. (B) TEM micrograph and DLS of DDC-Ncomp 






An extended rehydration time of 3 h was necessary to obtain only vesicular–shaped 
DDC-Ncomp (Figure 3.6A). When DDC-Ncomp was formed under these conditions, 
the presence of DDC and BSA in the lumen did not influence the polymersome 
structure, as judged from TEM micrographs, or the size of DDC-Ncomp, since DH 
remained constant (184 ± 66 nm) as determined by DLS (Figure 3.6B). Systematic 
investigation of factors affecting the self-assembly process and the enzyme activity 
(molecular properties of the copolymers and polymersome membrane, self-assembly 
conditions, stabilizer protein, reconstitution of holoenzyme) led to an optimized 




3.2.4 Surface functionalization of polymersomes with ssDNA 
With both imaging and therapeutic nanocompartments in hand, the next step 
consisted of functionalization with ssDNA to assemble them into theranostic clusters. 
Here again, different strategies had to be adopted to preserve DDC activity during the 
ssDNA functionalization of DDC-Ncomp and subsequent formation of clusters. The 
usage of PDMS22-PMOXA8-OEG3-N3 copolymer, consisting of short polymer chains 
Figure 3.6. Characterization of DCC-Ncomp. (A) Schematic representation of the 
formation of DDC-Ncomp. (B) Transmission electron microscopy (TEM) 





less entangled inside the polymersome membrane, promoted the coupling of the 
ssDNA by increasing the exposure of the azide terminal groups. We used 100 % of this 
azide-functionalized polymer to obtain the highest density of azide at the surface of 
polymersomes, thus enabling the attachment of a maximal number of ssDNAs. In 
addition, we investigated the influence of an additional spacer on the ssDNA sequence 
in facilitating the formation of dsDNA by hybridization, and thus the clustering of the 
complementary ssDNA-functionalized polymersomes.  
Dye-Ncomp is inherently stable, so its functionalization with ssDNAb or spacer-
ssDNAb was accomplished under normal conditions (37 °C, overnight) to obtain 
maximal reaction efficiency. To quantify the number of ssDNAb attached per 
polymersome, ssDNAb labelled with a fluorescent dye (Atto-488) were used to enable 
detection using fluorescence correlation microscopy (FCS). We confirmed that 
fluorescently labelled ssDNAb (without DBCO) did not interact with polymersomes, 
so that the count per molecule obtained for ssDNAb-functionalized Dye-Ncomp 
reflected only covalently attached ssDNA (Figure 10.2A) and did not affect the 
structure of polymersomes (Figure 10.2B). The number of ssDNAb attached per 
Dye-Ncomp can be determined by dividing the counts per molecule of ssDNAb-
functionalized polymersomes by the counts per molecule of free ssDNAb (Figure 
10.2C). We obtained an average value of 163 ± 61 of ssDNAb per Dye-Ncomp (Figure 
3.7A). Similarly, we determined the density of spacer-ssDNAb as 196 ± 96 spacer-
ssDNAb per Dye-Ncomp (Figure 3.7A, Figure 10.2). 
To avoid loss of the catalytic activity of DDC while performing ssDNA 
functionalization of DDC-Ncomp, we again had to optimize the reaction conditions. 
As described for DDC-Ncomp formation, we first investigated the feasibility of 
conducting ssDNA conjugation at 4 °C by using empty polymersomes (rehydrated with 
PBS only). DY-633-labelled ssDNAa and spacer-DNAa were used to assess the number 
of ssDNA covalently attached to polymersomes at 4 °C during overnight reaction 
(Figure 10.3A). The attachment of ssDNAa and spacer-ssDNAa to empty 
polymersomes was achievable under these conditions (Figure 10.3B), but the 
efficiency of the reaction was drastically reduced compared to the conjugation 
reactions at 37 °C. Under these conditions (4 °C, overnight) for functionalization of 
DDC-Ncomp, we obtained an average number of 23 ± 6 for ssDNAa and 22 ± 6 for 
spacer-ssDNAa attached per polymersome (Figure 3.7A). The functionalization of 





size, as determined by TEM and DLS (Figure 3.7C-F). Furthermore, the small 
amount of ssDNAa present at the surface of DDC-Ncomp should be counterbalanced 
by the large amount of complementary ssDNAb attached to the Dye-Ncomp, allowing 
the effective formation of theranostic clusters. 
 
Figure 3.7. Characterization of the ssDNA and spacer-ssDNA attachment on the 
surface of DDC-Ncomp and Dye-Ncomp. (A) Average numbers of ssDNA (solid) 
and spacer–ssDNA (stripped) linked to DDC-Ncomp (orange) and Dye-Ncomp 
(pink), as determined by FCS (n = 3; each sample was measured 30 times for 10s 
each). (B) Size of DDC-Ncomp linked with spacer–ssDNAa (orange) and Dye-
Ncomp (pink) linked with spacer–ssDNAb as determined by DLS. TEM 
micrographs of DDC-Ncomp linked with spacer–ssDNAa (C) and Dye-Ncomp 
linked with spacer–ssDNAb (D). TEM micrographs of DDC-Ncomp linked with 





3.2.5 Formation of DNA-linked clusters 
We investigated the cluster formation between DDC-Ncomp and Dye-Ncomp under 
mild conditions at 20 °C (Figure 3.8.A). We compared the clusters formed using 
polymersomes functionalized with ssDNA and those formed using spacer-ssDNA. 
After overnight incubation at 20 °C, no clusters were observed in the case of ssDNA-
functionalized polymersomes (Figure 3.8B, green line). In contrast, theranostic 
clusters formed rapidly when spacer-ssDNA was used (Figure 3.8B, blue line). These 
results support the idea that the spacer enhances the exposure of the complementary 
ssDNA sequences at the surface of polymersomes, resulting in easier hybridization of 
complementary strands to trigger the formation of clusters.122 The theranostic clusters 
formed using spacer-ssDNA rapidly self-organized into sub-micrometer-sized 
structures that further aggregated after 4 h (Figure 3.8). To slow the ssDNA 
hybridization process, so that the cluster size could be restricted, as well as to minimize 
loss of DDC activity, we investigated the formation of clusters at 4 °C using spacer-
ssDNA. But, as no clusters were formed after overnight incubation at 4 °C (Figure 
3.8C), we decided to control the size of the clusters by shortening the clustering time 
to 20 min at 20°C; this afforded theranostic clusters of around 531 ± 305 nm in size, 
with a polydispersity index (PDI) of 0.8 from three independent samples (Figure 
3.8D-E). To maintain the stability, these clusters were stored at 4 °C, where they 
showed long-term (at least one year) stability as the same size (495 ± 212 nm) was 















Figure 3.8. Characterization of theranostic clusters. (A) Schematic representation of the 
formation of theranostic cluster constituted by DDC-Ncomp and Dye-Ncomp linked 
together via hybridization of their complementary spacer–ssDNA, the spacer between the 
reactive DBCO moiety and ssDNA sequences used for hybridization (pink and orange) is 
represented in green. (B) The change of apparent size of theranostic clusters DDC-linked 
by ssDNA (green) and spacer–ssDNA (blue) as a function of time. The gray bars represent 
the standard deviation based on three independent experiments. (C) DLS showing that no 
clusters were formed using spacer-ssDNA for overnight at 4 °C. (D) TEM micrograph of 
theranostic cluster. (E) DLS of theranostic clusters. (F) DLS of theranostic clusters after 1 





The analysis of TEM microscopic images indicated that 87% of polymersomes were 
clustered and 13% remained nonbound. In general, clusters were composed of less 
than seven polymersomes (79%), with only 8% larger clusters composed of more than 
seven polymersomes (Figure 3.9A-B). These results suggest that the DDC-Ncomp 
and Dye-Ncomp form non-uniform random clusters with large distribution similarly 
to a previous observation122 but only a small fraction of larger clusters (clusters 
composed of ≥ 7 polymersomes) were formed. Larger clusters or small aggregates can 
be removed via size exclusion chromatography (SEC) or filtration. Furthermore, using 
a ratio of 2:1 DDC-Ncomp to Dye-Ncomp also promotes cluster formation at 20 C 
(Figure 3.9C); however, to achieve a balance between the imaging and therapeutic 
compartment, we used only a one-to-one ratio for the remained of experiments. The 
different strategy adopted to obtain a high density of ssDNAb per Dye-Ncomp enabled 
us to compensate for the low incorporation of ssDNAa per DDC-Ncomp obtained at 
the low temperature. Overall, the results indicate that incorporation of a spacer within 
the ssDNA facilitates the hybridization of ssDNA and promotes the formation of 







Figure 3.9. Characterization of polymersome clusters. (A) TEM micrographs 
showing the size and geometry of polymersome clusters. (B) Histograms showing 
the distribution of the number of polymersomes per cluster. The data were 
statistically analyzed using a binomial distribution based on 526 clusters in TEM 
micrographs. (C) DLS showing the size of clusters formed by mixing spacer-
ssDNAb functionalized Dye-Ncomp and spacer-ssDNAa at DDC-Ncomp/Dye-
Ncomp ratios of 2:1 and 1:2. Clusters were only obtained in the case of DDC-
Ncomp/Dye-Ncomp ratio of 2:1 after 20 min of incubation at 20 °C, as it is the case 
for 1:1 ratio (Figure 3.8E). For 2:1 and 1:2 ratios, no clusters were formed after 





3.3 Therapeutic potential of the theranostic clusters 
3.3.1 Determination of DDC-triggered production of dopamine 
We first estimated the DDC encapsulation efficiency in polymersomes using the model 
protein BSA, because of its similarity to DDC in size, molecular weight, and solubility 
(PDB ID: 3V03 and 3RBL); it is also an established model protein for UV-vis 
absorption measurements130–132 (see experimental chapter for further details). We 
obtained a value of 23.01 ± 6.03 DDC molecules per polymersome, representing an 
encapsulation efficiency of 15.6 ± 4.12 %, which is consistent with the range of 
encapsulation efficiencies generally obtained for enzymes within PDMS-PMOXA 
polymersomes.126 This provides a concentration of encapsulated DDC of 0.054 µg/mL 
for DDC-Ncomp and the corresponding clusters. 
Having determined the amount of encapsulated DDC per polymersome, we 
proceeded to assess the production rate of dopamine via irreversible decarboxylation 
of the substrate L-DOPA under physiological conditions.133 The production of 
dopamine by DDC was carried out for up to 24 h in PBS at 37 °C; however, both L-
DOPA and dopamine spontaneously auto-oxidize in vivo,134 and this also occurs in 
PBS, affording a dark, insoluble polydopamine precipitate.135 To overcome this 
problem, we decided to add a reducing agent during the DDC-triggered conversion 
reaction of L-DOPA to dopamine in PBS. We chose glutathione, the most abundant 
free thiol in mammalian cells, and a major antioxidant in the brain, where it is 
implicated in the prevention of L-DOPA and dopamine oxidation.136,137 As expected, 
no dark precipitate was formed in the presence of glutathione (Figure 10.4). The 
assessment of dopamine production by DDC was then possible by HPLC (Figure 
10.5), allowing us to calculate the percent conversion of L-DOPA to dopamine based 
on the areas under the corresponding peaks (Figure 3.10A). All percentages of 
conversion recorded correspond to dopamine production in the µM-mM range (the 
initial concentration of L-DOPA substrate was 0.49 mM).  
 
3.3.2 Catalytic activity of therapeutic polymersomes in situ 
Free (non encapsulated) DDC was first assessed to verify the role of BSA as a stabilizer. 





containing DDC in the presence of 0.1 wt% BSA, corresponding to the BSA 
concentration used in the rehydration solution to form DDC-Ncomp (Figure 3.10B, 
grey and black bars respectively). At all measured time points, the percent conversion 
of L-DOPA to dopamine in the presence of BSA was higher than in the case of the free 
DDC alone, confirming that BSA stabilizes DDC. 
Considering that the amount of Dopamine produced is closely related to the 
enzyme concentrations (Figure 10.6), to compare the activity of free DCC with that 
of encapsulated DDC inside DDC-Ncomp, as well as DDC-Ncomp clusters, we ensured 
that DDC was contained at the same concentration (0.05 µg/mL) in all samples. As 
shown in Figure 3.10, control DDC-Ncomp without OmpF did not show any 
conversion of L-DOPA since the polymersome membrane is impermeable (Figure 
3.10B, purple bars). Production of dopamine was observed when DDC was 
encapsulated in OmpF-equipped DDC-Ncomp, ssDNA functionalized DDC-Ncomp 
and DDC-Ncomp clusters with the imaging compartment (forming the 
nanotheranostic system). These results confirm the encapsulation of active DDC inside 
polymersomes, and the ability of the system to transport and convert L-DOPA and to 
release therapeutic dopamine (Figure 3.10B, orange blue and green bars). The 
percent conversion of L-DOPA to dopamine by encapsulated DDC is lower than that 
of free DDC in presence of BSA, presumably due to slow diffusion through the channel 
porin, resulting in a slower reaction in situ. The attachment of ssDNAa and subsequent 
clustering of DDC-Ncomp together with Dye-Ncomp also decreases the efficacy of 
conversion of L-DOPA to dopamine (Figure 310B, blue and green bars). This 
decrease in the DDC activity was expected, due to the inherent steric hindrance of 
OmpF by the ssDNA and ssDNAa-ssDNAb bridges formed during the polymersome 
clustering process. However, the amount of dopamine (µM) produced by the 
theranostic clusters is within the range required to induce a cellular response (Figure 
10.7). With regards to the reaction kinetics at physiological temperature (37 °C), we 
compared the conversion of L-DOPA to dopamine by free and encapsulated DDC at 
the beginning of the reaction (up to 2 h) and after 24 h (Figure 3.10B). Considering 
that the L-DOPA substrate is present in excess, the slower conversion rate observed 
after 24 h is not attributable to a decrease in substrate availability, but should reflect 







3.3.3 Stability of therapeutic polymersomes to thermal deactivation 
To gain insight into the thermal stability of DDC, we stored free and encapsulated DDC 
enzyme at 37 °C for different periods of time (0 to 2 h) prior to the addition of L-DOPA, 
and then measured dopamine production after 24 h (Figure 3.10C). Almost no 
dopamine was produced when free or encapsulated DDC was stored at 37 °C for 2 
Figure 3.10. Activity of DDC-Ncomp and theranostic clusters in PBS. (A) HPLC 
chromatograms showing elution peaks corresponding to dopamine (retention time 
10.1 min) and L-DOPA (retention time 11.8 min) for free DDC in PBS (gray), free DDC 
in the presence of BSA (black), DDC-encapsulating polymersomes (DDC-Ncomp, 
orange), theranostic clusters (blue), ssDNA-functionalized DDC-Ncomp (green), and 
control DDC-Ncomp without OmpF (purple), after reaction for 24 h at 37 °C. (B) 
Processed HPLC data showing the percent conversion of L-DOPA to dopamine by the 
different DDC-containing samples and assemblies, illustrating the kinetics of these 
systems up to 24 h at 37 °C in PBS. (C) Processed HPLC data showing the stability of 
these systems up to 2 h at 37 °C in PBS. (D) Processed HPLC data showing the stability 
of these systems up to 24 h at 4 °C in PBS. Full conversion (100% conversion) equates 





hours before addition to L-DOPA. These results confirm the rapid thermal inactivation 
of DDC at 37 °C, and support our explanation of the slower rate of dopamine formation 
after a longer reaction time at 37°C. To evaluate the stability of free and encapsulated 
DDC upon storage at a lower temperature, we repeated the same experiment at 4 °C 
(Figure 3.10D). The encapsulated DDC maintained a reasonably consistent percent 
conversion of dopamine up to one week, while free DDC showed a more pronounced 
decrease in dopamine formation (9.1% loss of dopamine production for free DDC with 
BSA, compared to 3.5% loss for DDC-Ncomp after 7 days). This behavior can be 
attributed to the stabilizing effect of polymersomes on DDC, in accordance with 
previous findings.138 Since no activity of encapsulated DDC was retained at 37 °C, we 
hypothesized that DDC is so sensitive to thermal denaturation that the stabilizing 
effect of polymersomes is only observable at low temperatures. Thus, even though 
polymersomes do not extend the active period of encapsulated DDC in PBS at 37°C, 
they still enhance the stability at 4°C, which may permit longer-term storage – a 
desirable feature for translational applications.  
 
3.3.4 Cell response to therapeutic polymersomes and theranostic clusters 
To investigate the ability of our therapeutic compartments and theranostic clusters to 
produce dopamine in vitro, we monitored the response of dopamine-sensing cells 
during incubation in the presence of DDC-Ncomp and corresponding DNA-linked 
polymersome clusters. We selected the HEKREWARD double-transgenic cell line as a 
dopamine-sensing platform; it was previously used to investigate the reward-based 
control of hypertension via a synthetic brain-dopamine interface.119 These cells were 
engineered to ectopically express human dopamine receptor 1 (DRD1), enabling 
dopamine-triggered production of the reporter, SEAP. SEAP is induced whenever the 
cells are exposed to dopamine; other metabolically related small molecules, such as L-
DOPA, did not trigger DRD1-driven SEAP expression. This HEKREWARD cell line is 
sensitive to dopamine in the nanomolar range, positioning it as a very sensitive and 
selective dopamine sensor. It has also been reported that the cellular expression of 
SEAP was the highest when the cells were incubated with dopamine for 3 days.119 The 
delay presumably reflects the fact that the response to dopamine requires time for the 





incubation time of 3 days for incubation of the DDC-Ncomp and theranostic 
polymersome clusters with cells. It should be noted that even though DDC showed 
reduced activity after 2 hours at physiological temperature in PBS, the production of 
dopamine reaches a concentration 31 µM, which is high enough to induce a relevant 
cell response.  
We first investigated the response of HEKREWARD cells when incubated with 
dopamine alone at various concentrations for 3 days. We observed a linear dependence 
of cellular expression of SEAP upon dopamine concentration up to 1 µM (Figure 
10.7). No further increase in SEAP expression was observed at higher concentrations 
of dopamine, and 12 U/L of SEAP was the highest cellular response achieved in our 
experiments (Figure 10.7). Second, we investigated the cellular response to 
dopamine produced by free DDC (Figure 3.11A). The maximum level of SEAP 
produced was 3 U/L (Figure 3.11B), probably due to the rapid deactivation of DDC 
as a result of the cumulative effects of physiological temperature and the cellular 
milieu. In these cellular assays, no change in SEAP production was observed with free 
DDC in presence of BSA (Figure 3.11B) or in PBS buffer only (Figure 10.8). This 
lack of a stabilizing effect of BSA on free DDC in cell assays could be explained by 
enhanced sensitivity of DDC under cellular conditions, as well as a dilution effect of 
BSA with other proteins. 
Interestingly, we observed higher levels of SEAP production in the presence of 
DDC-Ncomp in comparison with free DDC (Figure 3.11C). Our results clearly 
indicate the protective role of polymersomes in shielding DDC degradation in the 
cellular environment (Figure 3.11C): within the nanocompartments, BSA can 
continue to stabilize DDC and proteolytic degradation is avoided due to the polymeric 
membrane. DDC-Ncomp functionalized with ssDNAa, and also when present as 
therapeutic nanocompartments in the theranostic clusters, successfully induced a 
cellular response, of the same order of magnitude as DDC-Ncomp (Figure 3.11D, 
Figure 10.9). Notably, in the cell-based assay, the presence of ssDNAa and the 
location of DDC-Ncomp in theranostic clusters appears to compensate for the reduced 
activity observed in PBS, in agreement with other studies showing that catalytic 
nanocompartments were more active in cell media than in PBS as compared to free 
enzymes.126 This effect is most likely due to the shielding of polymersomes and to the 
presence of ssDNAa on the surface of the polymersomes, promoting the attachment of 





Such proximity with the cell membrane eventually leads to a locally increased 





Figure 3.11. Cell activation by DDC-Ncomp and theranostic clusters. (A) Absorbance monitoring of 
the enzymatic production of chromogenic p-nitrophenol from SEAP substrate p-nitrophenyl 
phosphate in the cell supernatant to assess cellular production of SEAP induced by different 
concentrations of free DDC (0.001–1 µg/mL) in the presence of 0.1 wt% of BSA. (B) Cell expression of 
SEAP (U/L) induced by different concentrations of free DDC (with BSA) after 3 days. (C) Comparison 
of cellular production of SEAP (U/L) induced by DDC-encapsulating polymersomes or free DDC in 
BSA, at 0.1 or 0.05 µg/mL DDC concentration. (D) Cell expression of SEAP (U/L) induced by free 
dopamine (dark blue), ssDNA functionalized DDC-Ncomp (green), DDC-encapsulating polymersomes 
(orange), DDCNcomp theranostic clusters (blue), control DDC-Ncomp without OmpF(purple), L-





3.4 Imaging potential of the theranostic clusters: cell attachment 
and tracking 
 
DNA-zipped polymersomes clusters possess interesting surface-binding ability to 
epithelial cells due to their physical properties118: their softness, increased size 
(unfavourable for endocytosis), and availability of ssDNA on the surface promote their 
attachment to scavenger receptors present at the surface of epithelial cells. Scavenger 
receptors are known to bind DNA, RNA and other negatively charged large 
molecules.139 Zeta potential measurements of our nanocompartments confirmed that 
ssDNA-functionalized polymersomes were more negatively charged (- 13.53 ± 2.54 mV 
for Dye-Ncomp and - 6. 93 ± 3.38 mV for DDC-Ncomp) than non ssDNA-
functionalized polymersomes (- 5.24 ± 0.4 mV), thus making them prime candidates 
for attachment to scavenger receptors. Since the HEKREWARD cell line used for our 
experiments is of epithelial origin, it should interact with ssDNA-functionalized 
polymersomes and clusters. To investigate the interaction between polymersome 
clusters and this new engineered HEKREWARD cell line, we used model systems: ssDNA-
functionalized polymersomes or DNA-linked polymersome clusters loaded with 
fluorescent dyes (DY-633 and Atto-488) as imaging compartments. The binding 
efficiency of spacer-ssDNA-bearing single polymersomes and DNA-linked 
polymersome clusters was investigated using confocal laser scanning microscopy 
(CLSM), at the same concentrations as used for the cellular assay. As expected, the 
single imaging compartments functionalized with spacer-ssDNA bound to the cell 
surface of HEKREWARD, whereas non-functionalized polymersomes showed lower 
attachment (Figure 10.10).  
To investigate whether the clusters also bind to the cell surface, as it was the 
case for the functionalized polymersomes, we loaded the therapeutic compartment 
with Atto-488 for visualization purposes and kept the imaging compartment loaded 
with DY-633 as described above (Figure 3.12, Figure 10.11). We incubated these 
dye-loaded clusters in the presence of the cells for 24 hours, then washed and imaged 
the cells to assess not only binding to the cell surface, but also whether or not the 
clusters maintain their bound conformation. For the theranostic system to function, it 
is imperative that the clustered architecture is maintained and that the two 





rigorous washing, we could indeed observe the colocalization of the Atto-488 and DY-
633 compartments, with a Pearson’s colocalization coefficient of 0.77 ± 0.09 (Figure 
3.12). The co-localisation observed for the two different compartments of the clusters 
demonstrates clustering of the nanocompartments and the stability of the DNA linkers 
in vitro (Figure 10.12). Considering the sensitivity and low lifetime of DDC, we 
wanted to determine how fast cell binding of the clusters occurs, as this would 
determine the overall efficacy of our system. For this experiment, we incubated the 
cells in the presence of the dye-loaded clusters and observed their attachment via 
CLSM live imaging. The results indicate that the cell binding process is fast, as 
fluorescence was apparent at the cell membrane within 10 min, and continued to 
increase thereafter (Figure 10.13). The fast binding of the DNA-linked polymersome 
clusters to the cell surface, before thermal deactivation of DDC can occur, is what leads 
to the locally enhanced production of dopamine, thus resulting in higher SEAP 
production as compared to that of the free enzyme observed in the cellular assay. This 
observation also confirms the ability of the dye-Ncomp to track itself and 
polymersome clusters over time in a biologically relevant milieu, supporting its 








Figure 3.12.  Cell attachment of theranostic clusters. (A) CLSM microscopic images 
from four different locations of 488-633-Ncomp clusters attached to the surface of 
HEKREWARD cells after incubation for 24 h, showing separate DY-633 and Atto-488 
channels, transmission channel and merged images (scale bar = 40 µm). (B) Merged 
DY-633 and Atto-488 channels of the two locations with colocalized regions 
appearing in white. Colocalization analysis of the two locations resulted in a 
Pearson’s coefficient of 0.77 ± 0.09. Scale bar = 90 pixels or 37.8 µm. (C) 3D rendering 
of recorded z-stack (left picture: y-axis and x-axis = 100 μm, z axis= 12 μm; right 





3.5 Modularity of polymersome clusters: a novel dual-functional 
platform 
 
Our strategy to obtain DNA-linked polymersome clusters for theranostics is modular, 
being based on four steps: 1- thin polymer film formation, 2- polymersome formation 
by self-assembly, 3- ssDNA coupling to the external surface of polymersomes and 4- 
clustering of loaded polymersomes into super-assemblies (Figure 3.13). Each of 
these steps had to be optimized in different ways to accommodate a biomolecule of 
choice (DDC), in a view of a targeted application for atherosclerosis treatment. 
However, our system is highly modulable as PDMS-PMOXA polymer of different 
molecular weights and varied types of biomolecules can be selected to match together 
(Figure 3.13A), and the conditions (temperature, time of reaction, concentrations) 
of each step can be optimized to allow the polymer/biomolecules combination 
(Figure 3.13B).109 Based on the many possibilities of adaptation, the super-assembly 
of DNA-linked polymersomes loaded with different active compounds represents a 





















Figure 3.13. Polymersome clusters as nanotheranostic platform. (A) Architecture 
providing therapeutic and diagnostic features. (B) The four steps involved in nano-





3.6 Conclusions   
 
We engineered a novel platform composed of segregated catalytic and imaging 
polymeric compartments linked together via DNA hybridization to form a modular 
nanotheranostic system. A combination of optimized construction approaches, i.e., 
high polymer concentration, short block-copolymers, short rehydration time, and low 
temperature, coupled with mild encapsulation conditions, permits the effective 
loading of DDC in the cavity of polymersomes, affording an active therapeutic 
compartment able to produce dopamine. The polymersomes protect DDC activity 
sufficiently during storage at 4 °C and also in cell media. As a result, active 
polymersomes encapsulating DCC and corresponding clusters trigger a cellular 
response via dopamine production and activation of dopamine receptors, with a 
response that is considerably enhanced compared to the case of free DDC.  
By employing a modular system, we were able to assemble the imaging 
compartment under harsher conditions that permitted a high encapsulation efficiency 
of the stable DY-633 dye and an increase in amount of attached DNA on the 
polymersome surface, compared to the therapeutic compartment. This enabled the 
successful formation of theranostic clusters via DNA-zipping. The presence of DNA on 
the surface of the therapeutic compartment affects the dopamine production rate by 
hindering the passage of substrate through the OmpF pore, but interestingly, in cell 
experiments, this DNA-associated loss of activity is compensated in the case of the 
theranostic clusters by the focused production of dopamine in close proximity to the 
dopamine D1 receptor. DNA promotes the attachment of polymersomes and clusters 
at the surface of epithelial cells, leading to an increased local concentration of 
dopamine at the cell surface, followed by efficient receptor activation.  
From a therapeutic point of view, dopamine activation of cell-surface dopamine 
D1 receptor molecules present on peripheral arteries has been shown to prevent 
atherosclerosis.140–142 Secondly, atherosclerosis can be regarded as a chronic 
inflammatory state that involves the presence of scavenger receptor-expressing 
macrophages in locations where atherosclerotic lesions are formed.143,144 By attaching 
the nanotheranostic clusters to these macrophages, we may be able to detect the early 
stages of artherosclerotic plaque formation as well as generate dopamine, preventing 





atherosclerosis are invasive and inadequate145 and therefore an early detection and 
prevention system such as our nanotheranostic platform could provide a much-needed 
alternative. 
Being constructed in a modular manner, these clusters offer extensive flexibility 
by an association of different polymersomes that can be tuned by a straightforward 
change of the enzymes or active compounds to provide a dual-functional solution for 
a large variety of pathological conditions. The stable architecture and tunability make 
these nanosystems a platform particularly suited for implementing this technology 
with possible additional modalities including targeting, responsiveness to pathological 



















4. Polymersomes as 
bioluminescent system for 
imaging applications 
 
This chapter introduces an artificial bioluminescent nanocompartment based on the 
encapsulation of light-producing enzymes, luciferases, inside polymersomes. We 
exploit nanocompartmentalization to enhance luciferase stability in a cellular 
environment but also to positively modulate enzyme kinetics to achieve a long-
lasting glow-type signal. These features pave the way for expanding 
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polymersomes to produce strong and long-lasting bioluminescence, Nanoscale, 







Bioluminescence, described as the production of light resulting from enzyme-
catalyzed reactions,147 is distinguished from other spectroscopy methods that rely on 
fluorescence or absorbance by superior sensitivity and a lower background. 
Bioluminescent systems possess unique advantages such as no light excitation 
requirement (as opposed to fluorophores), particularly strong signal output, and low 
background due to the lack of endogenous bioluminescent reactions in mammalian 
cells. Bioluminescence has been extensively exploited to develop in vitro and in vivo 
assays based on the real-time detection of light emitting enzymes (luciferases).148,149 
However, because the majority of luciferases have a short half-life or do not produce 
long-lived light signals, bioluminescence applications are largely restricted to 
genetically engineered cells with a constant expression of luciferase.150,151 Although 
high, but short-lived burst signals, i.e. flash-type kinetics afford high sensitivity, they 
are extremely complex to implement in an assay format, as special logistics and 
equipment (e.g. injectors) are required to not miss the signal.152 Current 
bioluminescent nanosystems are mainly based on nanoparticles (PLGA, gold, 
quantum dots) conjugated with luciferases for therapeutic, imaging or sensing 
applications, where the enzymes are exposed to the surface and subject to proteolytic 
degradation.150,151 
 Here, we aim to build a cell-free bioluminescent system with a sustained high 
luminescence output based on functional catalytic nanocompartments. We 
encapsulated a specific light-producing enzyme (Gaussia Luciferase, GLuc) inside the 
aqueous cavity of nano-sized polymeric vesicles (polymersomes), where the enzyme is 
protected and preserves its activity (Figure 4.1). When an appropriate substrate from 
the environment penetrates the polymersome, GLuc catalyzes the in situ production 
of bioluminescence, which represents the core functionality of the catalytic 
nanocompartments (GLuc Ncomp). Polymersomes have been reported to prolong the 
stability of encapsulated enzymes and increase the probability of enzyme-substrate 
interactions within the confined space.71 The polymeric membrane is equipped with 
channel proteins (Outer membrane protein F, OmpF) to render the membrane 
permeable for the passage of substrates and products. However, for channel proteins 





the polymersome cavity can decrease the in situ activity of the encapsulated 
enzymes.63,153 In our case, exploiting this diffusion process could allow a modulation 
of the enzyme kinetics to provide a stable bioluminescent system producing a long-





4.2 Physical characterization of bioluminescent polymersomes 
 
Polymersomes, depending on the properties of the copolymers forming the 
nanocompartment, offer advantages such as biocompatibility,67 low protein 
binding,154 high blood circulation times155, and escape from the immune system,154,156, 
and have thus proven their suitability for numerous applications (imaging, 
therapeutic, sensing).1 Compared to their lipid counterparts (liposomes), 
polymersomes not only possess greater mechanical stability while maintaining a soft 
Figure 4.1.  Scheme highlighting the concept of luminescence-producing 
Gaussia Luciferase nanocompartments (GLuc Ncomp). Light is produced 
upon addition of coelenterazine (substrate) that reaches the encapsulated 





architecture, but especially benefit from countless tunability possibilities based on 
associated chemistry.8,67,118,153,157 Thus, polymersomes are particularly suitable for the 
development of cell-free bioluminescent systems aiming at expanding the breadth of 
bioluminescence applications. We selected a poly(dimethyl siloxane)-block-poly(2-
methyl-2-oxazoline) (PDMS-PMOXA) polymer for its non-toxicity,67 stealth 
properties,154,156 short block length permitting membrane protein reconstitution,8,153 
self-assembly into polymersomes at high polymer concentration (10 mg/mL) and 
protective effect on enzymes from proteolytic degradation to enhance their half-life.158  
We synthesized the short-chained PDMS25-PMOXA10 diblock copolymer via 
sequential ionic polymerization34 (Figure 10.14-15) and built our functional catalytic 
compartment via film rehydration. The morphology of the resulting GLuc 
encapsulating polymersomes (GLuc Ncomp) was first characterized by Dynamic Light 
Scattering (DLS) (Figure 4.2A), from which we obtained an average apparent 
diameter (DH) of 189 ± 57 nm, with a polydispersity index (PDI) of 0.167. Their 
colloidal stability was also demonstrated as no aggregation was observed. Additional 
characterization was carried out by Static Light Scattering (SLS) to determine the 
radius of gyration (Rg = 105 nm). The hydrodynamic radius (Rh = 114 ± 17 nm) was 
obtained from the DLS profile (Figure 4.2B), leading to Rg/Rh = 0.92, consistent 
with a hollow spherical morphology of Gluc Ncomp.159 Finally, the variation in size of 
polymersomes as well as their morphology was visualized via Transmission Electron 
Microscopy (TEM), where we observed the typical collapsed architecture 
corresponding to soft polymersomes (Figure 4.2C). Neither the insertion of OmpF, 
nor the presence of enzymes inside the cavity of polymersomes affected the 
morphology or the dispersity of polymersomes, as shown by TEM and light scattering 
methods (Figure 10.16-17). The nanometer size range, high robustness, flexibility 
and strong colloidal stability of the PDMS-PMOXA polymersomes constitute desirable 











4.3 Catalytic activity of bioluminescent polymersomes 
 
Gluc, the encapsulated enzyme, is a widely used reporter enzyme that we selected for 
its small size (19.9 kDa), great thermostability, high intensity luminescence output, 
commercial availability and because it does not require a cofactor.152,160,161 GLuc 
produces a recordable light via enzymatic oxidation of its coelenterazine substrate, in 
the form of a flash-type kinetics that implies a strong albeit very prompt and transitory 
light signal making the detection difficult.152 By encapsulating GLuc within 
polymersomes (12 ± 5 % encapsulation efficiency), we aimed at modulating the flash-
kinetics to extend the luminescent signal over long periods of time (1 h) and also 
increase its stability in a cell environment. To investigate the effects of encapsulation 
on the enzymatic production of light, we compared the bioluminescence emitted by 
non-encapsulated (free) enzyme to the one produced by encapsulated enzyme (GLuc 
Ncomp), at equal final concentration (0.2 µg/mL).63,153,162 The typical flash-type 
kinetics of free GLuc was confirmed as after a fast transient burst, the signal quickly 
faded and was no more detectable after 5 min (Figure 4.3A). The advantage of 
encapsulating GLuc inside polymersomes is immediately observable as the enzyme’s 
kinetics is shifted towards a long-lasting light signal: after 1 min the luminescence 
signal of GLuc Ncomp overtakes that produced by free enzyme (Figure 4.3A). The 
encapsulation of GLuc enables the production of a signal that slowly increases to 
plateau at maximum intensity reached after 10 min and that is still readily detectable 
Figure 4.2.  Characterization of GLuc Ncomp. (A) Size determination of GLuc Ncomp measured by DLS. 
(B) Size determination of GLuc Ncomp measured by SLS: DLS profile showing the hydrodynamic radius 
(Rh) of GLuc polymersomes at different angles (cyan), the intensity at different angles (black) and the 
suitable MIE fit (grey) used to determine the radius of gyration (Rg). (C) TEM micrographs of GLuc Ncomp 





even after 1 hour. The permeability of polymersomes exclusively relies on incorporated 
transmembrane pores (OmpF), as the compactness of the polymeric membrane is not 
affected by the insertion of such pore-forming proteins. This long-lasting signal arises 
from the slow diffusion of the substrate coelenterazine through the OmpF pore to 
reach the encapsulated GLuc. In fact, OmpF has a molecular cutoff of 600 Da allowing 
smaller molecules such as coelenterazine (423.46 Da) to enter in the cavity of 
impermeable PDMS-PMOXA polymersomes.78,163 The resulting diffusion effect is the 
limiting factor for encapsulated enzyme efficiency, especially in our case as 
coelenterazine is uncharged and thus, its diffusion does not benefit from the attractive 
interactions that arise between zwitterionic molecules and charged residues of 
OmpF.164 The diffusion of bulky substrates through OmpF pores decreases the activity 
of encapsulated enzymes, so it is often perceived as a drawback for catalytic 
compartments, e.g. in applications like the in situ production of drugs.153 Here, this 
drawback is turned into an advantage as the slow diffusion of coelenterazine though 
OmpF enables a slow yet steady supply of substrate for the encapsulated enzyme as 
compared to free enzyme, resulting in the production of a persisting detectable signal 
(for at least one hour). This can be of particular advantage in applications like 
bioluminescence imaging as optical imagers equipped with charge-coupled device 
(CCD) cameras sum the photons detected during the measurement which results in 
the amplification of signal over the duration of recording.149 Moreover, in contrast to 
flash-type signals, such long-lasting luminescence offers greater accuracy as the 
maximum intensity signal occurs within a plateau. Long-lasting luminescence has 
already proven its attractiveness as it is akin to the glow-type luminescence of other 
kinds of luciferases (NanoLuc, Firefly Luciferase), which are particularly sought out 
for long-term recording in luminescence-based assays.148,160 While these enzymes have 
the appropriate glow-type luminescence, they often show poor stability and their 
expression depends on transfected cells, which again limits potential 
applications.148,160 
The same flash-to-glow switch of kinetics of GLuc Ncomp is maintained in cell 
medium even if the signal intensity is reduced compared to PBS for both free and 
encapsulated medium that slows down the diffusion of the substate but also from the 
slightly higher background luminescence obtained due to greater auto-oxidation of 





background is obtained for GLuc Ncomp without OmpF in the presence of 
coelenterazine, corroborating the absence of free or exposed enzymes (Figure 4.3B-
E). However, such backgrounds are negligible compared to the high luminescence 
signal obtained for free and encapsulated GLuc.  
 
 
4.4 Applicability of bioluminescent polymersomes 
 
Considering the importance of system stability for storage and applicability reasons, 
we showed activity retention of free and encapsulated GLuc up to 2 weeks of 
incubation in PBS and cell medium, at 4 °C and 37 °C (Figure 4.3C-F, Figure 
10.20-22). Furthermore, we demonstrated the protein repellence of our system as 
GLuc Ncomp did not substantially lose activity after 2 weeks of incubation in culture 
medium. This indicates that encapsulated enzymes are protected but also well 
Figure 4.3.  Activity of free and encapsulated Gaussia Luciferase (GLuc Ncomp). (A) Activity of GLuc 
Ncomp (cyan) and non-encapsulated GLuc enzymes (grey) in PBS and (B) corresponding controls: 
GLuc Ncomp without OmpF with substrate coelenterazine (purple), PBS alone with coelenterazine 
(green), GLuc Ncomp with OmpF without coelenterazine (dark blue, hidden by yellow), PBS alone 
without coelenterazine (yellow). (C) Remaining percentages of activity of free (grey) and encapsulated 
GLuc (cyan) in PBS, upon storage at 37 °C. (D) Activity of GLuc Ncomp and non-encapsulated GLuc 
enzymes in culture medium and (E) corresponding controls in culture medium. (F) Remaining 
percentages of activity of free (grey) and encapsulated GLuc (cyan) in culture medium, upon storage 
at 37 °C. The remaining percentage of activity were determined using the activity at t= 0 in PBS or 





supplied with substrate, which implies that OmpF is not obstructed as the passage of 
substrate is maintained. This preservation of activity of GLuc Ncomp reflects that 
protein adsorption (from the cell medium containing 10% fetal bovine serum) on the 
surface of polymersomes is predominantly absent and thus confirms the protein 
repellence of PMOXA based on its non-ionic nature. 154,156 Our system, by means of its 
stability and protein repellence possesses a certain potency that is essential for 
developing translational applications. 
Enzymatically-triggered coelenterazine oxidation can be exploited to develop 
redox sensors, as shown for our GLuc Ncomp in presence of ascorbic acid where the 
light signal is reduced in presence of this antioxidant (Figure 4.4A). It should be 
noticed that our system is scalable as this strong light signal results from a diluted 
sample of only 50 µL (0.5 mg/mL of GLuc Ncomp resulting in 0.2 µg/mL of GLuc). 
Therefore, both concentrations and volumes can be easily increased especially using 
our polymer that self-assembles at high concentrations, to reach even higher signals 





Figure 4.4.  Activity of GLuc Ncomp in different conditions. (A) Activity of 
GLuc Ncomp in PBS in presence of (0, 0.25, 2.5, 25 mM) ascorbic acid. Ascorbic 
acid reduce the production of light via prevention of the coelenterazine 
oxidation in a dose dependent manner. (B) Luminescence production at higher 
concentration of GLuc Ncomp (50 µL of 2 mg/mL, final concentration = 1 





To further probe the applicability of our system in a biological environment, we 
incubated GLuc Ncomp in the presence of cells (MCF-7) for 3 days and subsequently 
recorded their activity in the cell supernatant. GLuc Ncomp showed a signal similar to 
the one obtained in culture medium alone (Figure 4.5A, Figure 10.24), indicating 
that the activity is not affected by the presence of cells. In contrast, free GLuc showed 
decreased signal intensity in presence of cells compared to culture medium alone 
(Figure 4.5A), corroborating its premature degradation under biological conditions. 
The encapsulation within polymersomes improves the stability of GLuc by protection 
from harmful external milieu, e.g. proteolytic degradation (Figure 10.25).63 Such 
results highlight the advantage of GLuc Ncomp compared to free enzymes that are 
more likely to be degraded under biological conditions. Thus, by encapsulating the 
enzyme our polymersome-based system makes do without the cell’s continuous supply 
of luciferase and thereby warrants exploiting bioluminescence entirely cell-free. In 
addition, inside polymersomes, the shift to an extended, glow-type kinetics of GLuc is 
maintained under different conditions (with and without cells) which corroborates the 
integrity of the polymeric membrane, so the robustness of polymersomes even in the 
environment of cells.8,63,67,118,153,157 Additionally, GLuc Ncomps are not cytotoxic as the 
same cell viability is obtained in presence of GLuc Ncomps, free GLuc or PBS (Figure 
4.5B). Thus, our GLuc Ncomp system is of particular interest for biological 
applications as it is compatible with cells under physiological conditions and provides 
enhanced enzyme stability compared to free enzymes. 
To provide further indications about the potency of GLuc Ncomps for 
bioluminescence imaging applications, we carried out a preliminary in vivo study 
using mouse model. GLuc Ncomps (with or without OmpF for the control) were 
injected in the tail vein of mice, followed by the injection of coelenterazine 30 min 
later. After anaesthesia, the mice were imaged during 20 min when the photons were 
summed up to allow for quantification and provide an image indicating the location of 
the GLuc Ncomps (Figure 4.5C). We observed a strong bioluminescent signal in 
presence of GLuc Ncomps, while for the control, only a small signal was recorded, 
which probably arise from the background produced by coelenterazine auto-oxidation 
(Figure 4.5C). As we did not functionalized our polymersomes with targeting agents, 
GLuc Ncomps seemed to be spread in the mouse body, probably circulating in the 
blood stream. However, the primary goal of this experiment was to demonstrate that 





tissue, so had a real potential for being applied in pre-clinical research. In-depth study 




Figure 4.5.  Behavior of GLuc Ncomp in biologically relevant conditions. (A) Activity 
of GLuc Ncomp in culture medium (orange) or cell supernatant (cyan) compared to 
kinetics of free GLuc in culture medium (black) and cell supernatant (grey), after 3 days 
of incubation with cells. (B) Cell viability as percentage of control MCF-7 cells incubated 
with PBS (yellow), GLuc Ncomp (cyan) and free GLuc (grey). No significant decrease in 
viability is observed as compared to control cells, indicating the GLuc Ncomp and free 
GLuc are nontoxic. (C) Preliminary results of Bioluminescence Imaging (BLI). Pictures 
of BALB/c mice that have been injected with GLuc Ncomp (left) and GLuc Ncomp without 
OmpF (right). Two intravenous injection (IV) in the tail vein have been performed: 100 
μL of nanocompartment solution (2 mg/mL) followed by the injection of 100 μl 
coelenterazine after 30 min. The luminescence intensity has been recorded for 20 min 







We developed the first artificial bioluminescent nanocompartment with high potential 
as cell-compatible yet cell-independent bioluminescent system that overcomes the 
need for using cells transfected with luciferase gene constructs. We also pinpoint that 
the diffusion of coelenterazine into the nanocompartment, afforded by the membrane 
insertion of porins, can be exploited to achieve more suitable kinetics. By means of 
polymersomes confining Gaussia Luciferase, our system enables a favorable switch in 
kinetics towards a glow-type luminescence to reach long-lasting but still powerful light 
signal. Compartmentalization not only allows for tuning signal output but also 
stabilizes the encapsulated enzyme in a cell environment. Thus, our system overcomes 
the restrictions arising from enzyme degradation and those related to quick fading of 
the signal, which positions these bio-hybrid catalytic nanocompartments as potent, 
cell-free alternative. In addition, the long-lasting and powerful light signal produced 
by our system was able to be detected in vivo through biological tissues, thus showing 
its potential for in vivo bioluminescence imaging. The intrinsic properties (e.g. 
robustness, non-toxicity) and tunability of polymersomes could be an attractive 
extension that could be exploited for developing in vitro assays (redox sensing 
applications)166 or specific preclinical imaging methods (e.g. detection and targeting 
of tumours). This new bioluminescent nanosystem, based on an artificial bio-hybrid 
nanocompartment, is expected to overcome cell-related restrictions and thereby 
greatly expand the usage of both nanotechnology and bioluminescence in biomedical 
domains. Further studies are required to assess the biodistribution and clearance of 
these polymersomes as their application for in vivo imaging will greatly depend on 











5. Polymersome-based artificial 
melanosomes 
 
This chapter describes the development of bio-hybrid polymersomes as melanosome 
mimics for cell photoprotection applications like in the prevention of skin cancers. 
Inspired by nature, we built nanocompartments encapsulating melanin or 
polydopamine to recreate the native architecture of melanosomes. This way, we 
aimed at exploiting the polymeric membrane to shield the main drawbacks of 
melanin/polydopamine, i.e., cytotoxicity and compromised colloidal stability, while 
maintaining the UV-absorption properties. The achievement of such system was 
possible using a short-chained polymer that self-assembles into polymersomes, 
encapsulating L-DOPA or dopamine precursors together with melanogenic enzyme 
Tyrosinase, prior to melanin/polydopamine polymerization. Our system highlights 
a new strategy to contain melanin/polydopamine drawbacks, thus expanding the 
possible applications of these macromolecules, and provide a novel system with 
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Melanin is a natural biopolymer that is spread throughout the body and responsible 
for hair, eye and skin pigmentation, where its dark color effectively absorbs light. 
Melanin pigment is synthesized and deposited in specific organelles, termed 
melanosomes, that protect the outer-most layer of the skin, the epidermis, from UV-
related damages.167 Initially produced in melanocytes residing in the basal layer of the 
epidermis, mature melanosomes are transported to neighboring keratinocytes where 
their arrangement into a supranuclear cap around the nucleus protects DNA from UV 
radiation.167 Thus, intact melanosomes are essential actors in the prevention of skin 
cancer. Several diseases are associated with defective melanosomes. In Vitiligo, 
melanocytes and thus melanosome biogenesis are lost whereas Albinism causes a 
shortage of tyrosinase, the key enzyme involved in eumelanin synthesis in 
melanosomes.168,169 To date, no efficient treatment exists for such diseases. This calls 
for the development of alternatives such as synthetic melanosomes, in particular as 
the risk of contracting skin cancer is on the rise.168,169 
Due to size similarity, melanosomes can be mimicked using various colloidal 
nanomaterials such as natural melanin, in order to remain close to biological systems. 
As the extraction of melanin from its natural source remains complex and hardly 
reproducible, in vitro synthesis is usually indicated. For example, the oxidation of 
substrate L-DOPA is enzymatically-triggered by Tyrosinase to form a heterogenous 
melanin biopolymer. Synthetic melanin has also been used to coat silica nanoparticles 
for applications like bone marrow protection upon radiation therapy or as 
antioxidant.170,171 Despite considerable efforts, the macromolecular structure of native 
melanin is poorly understood and its application has been neglected due to the rising 
popularity of its synthetic counterpart polydopamine (PDA).172 Despite molecular 
differences, PDA shares some properties with melanin, e.g., UV-absorption, but has 
been widely preferred due to easier synthesis.173 PDA nanoparticles form upon 
spontaneous oxidation of dopamine under alkaline conditions. Extensive studies have 
shown the potential of PDA nanoparticles as imaging agents, drug carriers, 
antioxidants or microparasols for UV-protection.172,174 Various PDA-based 
nanoparticle architectures can be developed depending on its association with other 





nanoparticles and polymeric surfactant have led to mesoporous PDA nanoparticles 
with intrinsic cavities.175 Different nano objects, e.g., liposomes or polymeric 
nanospheres, have been used as PDA-coated templates to form shell-like or 
multicompartment structures.98,176,177 
However, melanin- or PDA-based nanoparticles barely represent the vesicular 
architecture of native melanosomes where melanin is enclosed within a phospholipidic 
membrane rather than being exposed at the surface, as is the case for most melanin- 
and PDA-based nanoparticles.167,172 The cytotoxicity of melanin and PDA (under 
certain conditions) and the often compromised colloidal stability of melanin- and 
PDA-based nanoparticles prompted us to investigate whether these drawbacks could 
be solved by biomimicking native-like architectures.172,176,178–182 In this regard, soft-
nanocompartments, i.e., liposomes and polymersomes that are composed of an 
amphiphilic membrane enclosing an aqueous cavity appear as potent nanomaterials 
to build melanosome mimics as their architecture resembles biological vesicles. 
Polymersomes possess the advantage of increased mechanical stability and broad 
chemical versatility over liposomes.1 In addition, polymer-based vesicles are 
frequently non-toxic and enable the integration of a variety of hydrophilic and 
hydrophobic molecules, be it embedded in their membrane, covalently attached to 
their external surface or enclosed within their cavity.1,67 Thus, polymersomes are well 
suited for many applications including sensing, drug production/delivery, imaging, 
theranostics and last but not least as artificial organelles.1,113 
Here, we investigated the potential of biomimicking the vesicular structure of native 
melanosome for avoiding the main pitfalls of melanin/PDA-based nanoparticles that 
are cytotoxicity and reduced colloidal stability (Figure 5.1). We developed different 
melanosome mimics composed of polymersomes encapsulating melanin or PDA. L-
DOPA or dopamine precursors together with Tyrosinase were encapsulated inside 
polymersomes and subsequently incubated to induce polymerization into melanin or 
PDA in the polymersome cavity. We synthesized a short-length diblock co-polymer of 
poly(dimethylsiloxane)-block-poly(2-methyloxazoline) (PDMS24-PMOXA12) that self-
assembles into polymersomes in less than 30 min. This time frame is short enough to 
encapsulate L-DOPA and dopamine before they polymerize, resulting in intact 
polymersomes with no aggregation tendency. We investigated the differences between 
melanin-and PDA-polymersomes in terms of UV-absorption properties, cytotoxicity 





and PDA formation within polymersomes where the confining membrane provides a 
novel kind of shield against aggregation and cytotoxicity of melanin and PDA while 
UV-absorption properties are maintained. Our system breaks ground for a new 
biomimetic strategy based on the encapsulation of melanin/PDA. As proof of 
principle, we explored biological applications of such melanosome mimics and provide 
an indication of the potency of our system for cell-photoprotection. Future 
developments of our basic Melanin/PDA polymersomes should lead to new 
nanosystems with increased applications. 
 
5.2 Physical characterization of melanosome mimics 
 
Melanin- and PDA-based particles results from a supramolecular buildup involving 
consecutive protoparticle (10-9 m) agglomeration to bigger architectures (10-8 - 10-7 m). 
The formation is enigmatic and hardly controllable despite being key to fully exploit 
the potential of these materials.183 For these reasons, melanin and PDA have been 
predominantly used as coating for various materials rather than as nanoparticles. In 
coating procedures, the deposition on the substrate can be limited by immersion time 
of the substrate into melanin/PDA solutions.172 Given the strong tendency of melanin 
and PDA to randomly accumulate on various materials, the formation of 
Figure 5.1. Scheme representating the differences between melanin/PDA nanoparticles and 





polymersome-based melanosomes mimics required a strategy for containing 
aggregation such that the self-assembly of polymersomes is not impeded by 
aggregation of the polymers with melanin/PDA. For this reason, we investigated the 
possibility of encapsulating melanin/PDA precursors (L-DOPA/dopamine) together 
with Tyrosinase inside polymersomes before polymerization occurs.  
As base element for our artificial melanosome, we chose a PDMS-PMOXA 
copolymer for its biological compatibility (stealth, non-toxicity), its mechanical 
stability and impermeability to small molecules.67,106,153,154,156 More specifically, we 
synthesized via sequential ionic polymerization, the short-chained PDMS24-PMOXA12 
to allow for fast self-assembly of polymersomes (Figure 10.26-27). To initiate self-
assembly into melanin- or PDA-polymersomes, a solution of L-DOPA or dopamine 
was added to a PDMS24-PMOXA12 thin film together with Tyrosinase. However, under 
conditions conducive to polymersome formation (room temperature for 12 h),58,153,159 
no polymersomes were formed but instead, a brown-black sticky material was 
obtained which obstructed the stirring (data not shown). Thus, the conditions were 
adapted to achieve encapsulation of L-DOPA/dopamine and Tyrosinase into 
polymersomes prior to polymerization into melanin/PDA: Polymersome formation 
was carried out at 4 °C for a short time (30 min), the self-assembled structures were 
extruded and subsequently purified by size exclusion chromatography (SEC) to 
remove the unencapsulated L-DOPA/dopamine and Tyrosinase. We previously 
reported the ability of specific PDMS-PMOXA to rapidly self-assemble into 
polymersomes at 4 °C.153 However, it is the first time that polymersome formation was 
achieved at 4°C in as little as 30 min which is afforded to the short block-length of our 
polymer and its polydispersity (Đ = 1.16) that promote self-assembly. The presence of 
L-DOPA/dopamine and Tyrosinase affected neither the self-assembly process, nor the 
architecture of the resulting polymersomes, as shown by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS) (Figure 5.2). A size of 178 ± 
70 nm was obtained by DLS for Melanin-polymersomes (Figure 5.2A) and 173 ± 68 
nm for PDA-polymersomes prepared with Tyrosinase, which is consistent with the size 
of control polymersomes rehydrated under the same conditions with PBS (172 ± 63 
nm) or Tyrosinase only (165 ± 49 nm). Melanin- and PDA-polymersomes prepared 
without Tyrosinase showed a similar size and morphology (Figure 10.28). 





of the native organelle which greatly varies depending on the ethnicity and skin 
condition (100 - 800 nm).167,184,185  
Figure 5.2. TEM micrographs and corresponding DLS, showing the morphology and 
size of (A) Melanin-polymersomes (with Tyrosinase), (B) PDA-polymersomes (with 






Also, the number of Melanin-polymersomes (2.21*1012 vesicles/mL), PDA-
polymersomes (2.15*1012 vesicles/mL) (prepared with Tyrosinase) and Tyrosinase-
polymersomes (2.14*1012 vesicles/mL) quantified by nanoparticle tracking analysis 
(NTA) was similar to that of control polymersomes containing only PBS (2.06*1012 
vesicles/mL), indicating that neither L-DOPA/dopamine, nor Tyrosinase interfered 
with the polymer self-assembly into polymersomes (Table 2). These results were 
expected as PDMS-PMOXA polymersomes are known for their robustness and ability 
to encapsulated various active compounds and biomolecules.100,146,153 
 
Sample Concentration (vesicles/mL) 
Melanin-polymersomes (w/o Tyrosinase) 1.94*1012 ± 1.69*1011 
PDA-polymersomes (w/o Tyrosinase) 1.82*1012 ± 1.97*1011 
Melanin-polymersomes (w/ Tyrosinase) 2.21*1012 ± 0.79*1011 
PDA-polymersomes (w/ Tyrosinase) 2.15*1012 ± 2.59*1011 
Empty polymersomes 2.06*1012 ± 1.09*1011 
Tyrosinase-polymersomes 2.14*1012 ± 1.24*1011 
 
Table 2. Nanoparticle Tracking Analysis (NTA) results showing the concentration of polymersomes 
(vesicles/mL) for a concentration of 1 mg/mL of polymersomes. 
 
5.3 Colloidal stability of melanosome mimics 
 
While the supramolecular buildup of melanin from precursors remains unclear, its 
molecular structure has been identified as an heterogenous macromolecule composed 
of 5,6-dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylique acid (DHICA) 
at variable ratios.186 Tyrosinase is the key enzyme of melanogenesis, as it is involved 
in several oxidation steps: from the initial precursor L-Tyrosine to L-DOPA, from L-
DOPA to DOPAquinone, and later from DHI to indole-5,6-quinone (Figure 5.3).187 
We chose to encapsulate L-DOPA or dopamine together with Tyrosinase inside 





respectively. We chose L-DOPA as the initial precursor as it is rather stable (compared 
to highly reactive quinone), has higher solubility than L-Tyrosine, and because the use 
of downstream precursors is known to decrease the chemical versatility of the melanin 
produced. For example, DHI and DHICA predispose the resulting melanin structure 
towards DHI- or DHICA-derived melanin that have distinct properties.183 The 
structure of PDA differs from that of melanin as in PDA, monomers interact through 
π-π stacking and hydrogen bonds rather than covalent bonding.183,188 Although PDA 
forms upon autoxidation of dopamine, we also studied the effect of Tyrosinase on PDA 







Figure 5.3. Pathways leading to the synthesis of DHI-based and DHICA-based melanin/PDA, starting 





We estimated the concentration of encapsulated L-DOPA (0.13 mM), dopamine (0.11 
mM) and Tyrosinase (0.28 µM) for corresponding polymersomes (1 mg/mL) based on 
the ratio of the starting concentration (used for film rehydration) and the 
concentration of unencapsulated compounds determined by measuring the 
absorbance in fractions collected from SEC purification (see Materials and Methods). 
The resulting encapsulation efficiencies obtained for L-DOPA (13 ± 3 %) and 
dopamine (11 ± 5 %) were lower than what is usually obtained for encapsulation of 
small molecules, which probably results from stacking and electrostatic interactions 
of these respective catecholamines making them tedious to encapsulate. Tyrosinase 
encapsulation efficiency (9 ± 4 %) was within the range usually obtained for enzyme 
encapsulation inside polymersomes.63,146,153,190 We ruled out the presence of L-DOPA, 
dopamine or Tyrosinase adsorbed to the outer surface of polymersomes as similar zeta 
potentials were obtained for Melanin-Polymersomes with Tyrosinase (-3.29 ± 0.62 
mV), PDA-polymersomes with Tyrosinase (-2.93 ± 1.02 mV), Melanin-polymersomes 
without Tyrosinase (-2.87 ± 0.54 mV), PDA-polymersomes without Tyrosinase (-2.63 
± 0.36 mV), Tyrosinase-polymersomes (-3.11 ± 0.82 mV) and empty polymersomes (-
2.81 ± 0.63 mV). Additionally, we performed a control experiment where empty 
polymersomes (formed with PBS only) were mixed with 100 times lower of L-
DOPA/dopamine (10 µM) and Tyrosinase (30 nM) concentrations than the 1 mM L-
DOPA/dopamine and 3 µM Tyrosinase used film rehydration. As shown in Figure 
5.4, the presence of a small amounts of L-DOPA and dopamine outside polymersomes 
resulted in the clustering of polymersomes after one week of incubation at 37 °C, 
followed by extensive aggregation. In contrast, no aggregation or clustering was 
observed for the melanosome mimics, corroborating the absence of adsorbed 






 Indeed, Melanin-polymersomes and PDA-polymersomes showed high colloidal 
stability as their size was maintained even after 6 months of storage at 37 °C (Figure 
5.5, Figure 10.29). Hence, by means of encapsulating precursors and Tyrosinase in 
polymersomes, we introduce a unique approach to preventing melanin and PDA 
aggregation which could open new avenues for applying these materials. In addition 
to keeping enclosed light absorbing biopolymers to prevent aggregation, we predict 
the polymeric membrane to simultaneously confine melanin- and PDA-associated 
cytotoxicity while their UV-absorption properties are preserved. 
Figure 5.4. TEM micrographs of polymersome clusters collected in 
the supernatant of solution containing empty polymersomes in 
presence of (A) L-DOPA with Tyrosinase, (B) Dopamine with 
Tyrosinase, (C) L-DOPA, (D) Dopamine, after one week of 








5.4 UV-absorption properties of melanosome mimics 
 
Owing to their strong absorption properties, broad-band UV-Vis absorption spectra 
have been considered the cornerstone for monitoring melanin and PDA 
polymerization.171,172,188 Thus, we examined melanin and PDA formation within the 
polymersome cavity (with and without co-encapsulated Tyrosinase) by measuring 
absorbance from 250 to 700 nm up to 24 hours (Figure 5.6). The absorption 
spectrum for all polymersomes encapsulating L-DOPA or dopamine (with and without 
Tyrosinase) showed an upward shift indicative of melanin/PDA compared to control 
polymersomes (empty polymersomes or polymersomes encapsulating only 
Figure 5.5. TEM micrographs showing the morphology of (A) 
Melanin-polymersomes (with tyrosinase), (B) PDA-polymersomes 
(with tyrosinase), (C) empty polymersomes rehydrated with PBS 
only, (D) Tyrosinase polymersomes, (E) Melanin-polymersomes 
(without tyrosinase) and (F) PDA-polymersomes (without 





Tyrosinase) where no shifts were obtained even after 24 hours (Figure 5.6). The 
presence of Tyrosinase (Figure 5.6D,F) led to a higher absorption for L-DOPA- and 
Dopamine-polymersomes, showing that the enzyme promotes the production of 
melanin/PDA. In the absence of Tyrosinase (Figure 5.6C,E), a plateau occurred 
around 450 nm, suggesting that a certain amount of DOPAchrome/dopamine-chrome 
did not spontaneously convert (via decarboxylation) into DHI and thus polymerization 
did not proceed.191 Indeed, the intramolecular cyclization of DOPAquinone (via 
DOPAchrome intermediate) to DHI is known to be very slow.192 Interestingly, in the 
presence of Tyrosinase, no unconsumed DOPAchrome/dopamine-chrome was 
observed, even though Tyrosinase is not directly involved in the Dopa-quinone to DHI 
conversion (via DOPAchrome intermediate) (Figure 5.6D-F).187 However, 
Tyrosinase triggers the formation of DOPAchrome precursor (DOPAquinone) and the 
conversion of DOPAchrome product (DHI) into reactive indole-5,6-quinone.187 Thus, 
it is conceivable that Tyrosinase affects the DOPAchrome/dopamine-chrome 
formation or the conversion to DHI by influencing the equilibrium of intermediates 
resulting from previous or later reaction steps. This hypothesis is supported by the 500 
nm absorption shift obtained for L-DOPA polymersomes in presence of Tyrosinase, 
indicating the formation of DHI-derived melanin (Figure 5.6D).193 Accordingly, a 
darker coloration of Melanin-polymersome/PDA-polymersomes was visible by eye, 
consistent with the fast oxidative polymerization of DHI (Figure 5.6G), as opposed 
to DHICA-derived melanin that is known to be formed slower and result in a color-
less solution, even after 24 h of reaction.194 These results support that Tyrosinase 
favors the formation of DHI-derived melanin rather than DHICA-derived melanin 
which is an advantage as DHI-melanin possesses increased visible light absorption 
properties.183 Notably, PDA-polymersomes showed stronger absorption compared to 
Melanin-polymersomes over a broad-range of wavelengths (Figure 5.6D,E). It 
appears reasonable that the formation of PDA occurs more readily because it mainly 
involves fast occurring non-covalent interactions (charge transfer, π-stacking, 
hydrogen bonding) rather than covalent linkage among units as it is the case for 
melanin formation.188 These data suggest that PDA-polymersomes have an enhanced 









As the concentration of encapsulated L-DOPA/dopamine obtained for our 
melanin- and PDA-based melanosomes mimics is in the lower range of standard 
concentrations (25 µM - 100 mM) used for the formation of Melanin and PDA 
nanoparticles195,196, we used high concentrations of polymer (10 mg/mL) to obtain 
concentrated polymersomes solutions (around 2*1012 vesicles/mL), showing light-
Figure 5.6. Melanin and PDA formation within polymersomes monitored via UV-vis spectroscopy and 
SLS. Absorption spectrum (left panels) measured at t = 0 (grey), t=12 h (cyan) and t=24 h (orange) of 
incubation at 37 °C, and SLS data (right panels) measured at 24 h of (A) Empty polymersomes, (B) 
Tyrosinase polymersomes, (C) L-DOPA polymersomes, (D) L-DOPA polymersomes (with Tyrosinase), (E) 
Dopamine polymersomes, (F) Dopamine polymersomes (with Tyrosinase). SLS data are composed of a DLS 
profile showing the hydrodynamic radius (Rh) at different angles (cyan), the normalized intensity at 
different angles (black) and a corresponding MIE fit (grey). (G) Snapshots showing the color of the solution 






absorption properties (Table 2, Figure 5.6). Furthermore, PDMS-PMOXA 
polymersomes are known to be impermeable to small molecules but allow the 
diffusion of molecular oxygen.1,197 Thus, encapsulated L-DOPA/dopamine is unable to 
diffuse out of the polymersome while oxygen can freely diffuse across the polymer 
membrane and mediate auto-oxidation or enzyme-catalyzed oxidation of 
encapsulated compounds, which leads to L-DOPA/dopamine polymerization inside 
the polymersome cavity. Control experiments with free L-DOPA/Dopamine were 
performed under corresponding conditions, i.e. solutions of L-DOPA/Dopamine 
(0.13/0.11 mM) were incubated at 37 °C with or without Tyrosinase (3 µM) (Figure 
5.6G) to test whether melanin/PDA formation takes place at these concentrations, 
temperature and time. As shown in Figure 2G (bottom panels), we observed a rapid 
change in color with subsequent aggregation, indicating that melanin/PDA are formed 
(Figure 5.6G, Figure 10.30). Similar to the Tyrosinase-related color change 
observed in polymersome samples, the enhancing effect of Tyrosinase was observed 
with free L-DOPA/dopamine, supporting its contribution to obtaining light-absorbing 
materials. 
In addition, the aggregation of melanin/PDA in solutions provides further 
evidence for the low colloidal stability of such materials compared to when 
encapsulated inside polymersomes (Figure 5.6G, Figure 10.30). Inside 
polymersomes, the aggregation process is most likely terminated by the limited 
amount of L-DOPA/Dopamine available. To gain insight into the buildup of 
melanin/PDA inside polymersomes, we performed Static Light Scattering (SLS) 
experiments to determine the radius of gyration (Rg) of polymersomes (Figure 5.6A-
F, right panels). With the hydrodynamic radii (Rh) derived from the DLS profiles, a 
ratio 0. 775 < Rg/Rh ≤ 1 was calculated for all Melanin/PDA polymersomes (with and 
without Tyrosinase) and control polymersomes (empty or encapsulating Tyrosinase 
alone), which indicates a hollow spherical morphology of polymersomes in the absence 
of an optically dense core.159 Thus, the formation of a single, large melanin/PDA 
nanoparticle in the polymersome’s interior can been excluded. Additionally, as an 
Rg/Rh = 1 indicates an infinitely thin membrane and the Rg/Rh for all polymersomes 
was closer to 1 than to 0.775, we ruled out the possibility of a thick melanin/PDA 
coating at the inner membrane surface of the polymersome. We concluded that 
melanin/PDA within polymersomes was probably present as oligomers and/or lower-





Tyrosinase-mediated formation of melanin in solution lead to melanin protoparticles 
(6 nm of diameter) when the reaction was induced in a restricted area.183,198,199 Based 
on our data showing that by sequestering L-DOPA/dopamine inside polymersomes, 
melanin/PDA production without large scale aggregation while maintaining 
interesting light-absorption properties is feasible, and in view of biological 
applications of such melanin/PDA-polymersomes, we addressed on the interactions 
of our melanosome mimics with cells. 
 
5.5 Cytotoxicity and potential cell photoprotection activity 
 
Although melanin is a biological pigment and PDA functions in a large variety of bio-
applications, both materials can be cytotoxic, as they can promote lipid peroxidation 
upon UV irradiation, leading to increased cell death.178,179,182 It has also been reported 
that a smaller diameter of PDA particles and an increased concentration favor 
cytotoxicity.182,200 To test the cytotoxicity of our melanosome mimics, we carried out a 
cell-proliferation assays with the keratinocyte cell line HaCatT (Figure 5.7A). After 1 
day of incubation with polymersomes at high concentration (0.25 mg/mL), we did not 
observe cytotoxicity of our melanin/PDA polymersomes or control polymersomes.  
 
Figure 5.7.  Interaction of polymersome-based melanosome mimics with HaCaT cells. (A) Cell 
proliferation assay showing the non-toxicity of different kinds of polymersomes compared to 
PBS. (B) Cell proliferation assay showing the cytotoxicity of free L-DOPA/dopamine (with and 






As comparison, we carried out the same experiment with melanin/PDA formed in 
solution under corresponding conditions and found significant toxicity compared to 
PBS or a control solution containing only Tyrosinase (Figure 5.7B, Figure 5.8). 
 
 
The apparent cytotoxicity probably arose from the large melanin/PDA aggregates that 
hinder cell proliferation when no measures are taken to limit the aggregation of 
melanin/PDA (Figure 5.8, Figure 10.31). Thus, our polymersome-based 
melanosome mimics, via sequestering of melanin/PDA not only prevent aggregation 
of melanin/PDA, but elude cytotoxicity which drastically increases their suitability for 
biological applications.  
Additionally, we tested the cytotoxicity of our melanosome mimics after 
irradiating cells for 40 min with UV and observed no increase in cell death compared 
to PBS, suggesting the absence of UV-triggered damaging reactions for melanosome 
mimics and control polymersomes (Figure 5.9A). On the contrary, we observed an 
enhanced cell viability in the presence of PDA-polymersomes (with Tyrosinase), 
Figure 5.8. CLSM images showing cell death (round cells) induced by 
aggregates of melanin/PDA previously formed in presence or absence of 





suggesting protection against UV damage. These data are consistent with the 
absorbance spectra presented in Figure 5.9, where PDA-polymersomes showed the 
highest absorption, suggesting that UV-protection properties are possibly increased 
compared to melanin-polymersomes (Figure 5.9). However, we deem the amount of 
polymersomes entering cells is too low for melanin-polymersomes to act as a 
detectable UV-shield for the nucleus. Confocal laser scanning microscopy images of 
HaCaT keratinocytes treated with control polymersomes encapsulating Atto-488 
fluorescent dye reveal that our polymersomes have the ability to enter cells where they 
localize around the nucleus albeit to a limited extent (Figure 5.9B). In view of 
possible photoprotection applications, in-depth cell studies are needed to unravel the 
fate of polymersome-based melanosome mimics inside cells (uptake, endosomal 
escape and perinuclear accumulation). Moreover, improvements to the melanosome 







Figure 5.9. Interaction of polymersome-based melanosome mimics with HaCaT cells. (A) Cell 
proliferation assay showing the cytotoxicity/cell protection effect of different kinds of 
polymersomes after 40 min of UV-irradiation of cells. (B) CLSM images showing perinuclear 
localization of model polymersomes (encapsulating fluorescent Atto-488) in keratinocytes. 







Biomimetic synthesis of melanin mediated by Tyrosinase is the synthetic route that 
comes closest to native melanogenesis.183 By reproducing for the first time this process 
in the confined environment of a soft nanocompartment, i.e., inside polymersomes, 
we closely mimic the natural pathway of melanin biosynthesis in melanosomes. For 
comparison, we produced polydopamine (PDA), which is considered a synthetic 
melanin, within the cavity of polymersomes in a similar fashion. Being an emerging 
biopolymer material with interesting coating properties, PDA is gaining increasing 
attention and might even be more applicable than melanin. By the specific selection of 
a short-chained PDMS-PMOXA polymer, both polymersome-based systems showed 
great colloidal stability, UV-absorption properties as well as the absence of cytotoxicity 
and a potential for cell photoprotection. The sequestering of melanin/PDA inside 
polymersomes is a new way of avoiding aggregation, even over extended periods of 
time, that is generally difficult to achieve with melanin/PDA nanoparticles. At the 
same time, the polymeric membrane enclosing melanin/PDA acts as a barrier 
preventing cytotoxicity that typically goes hand in hand with non-encapsulated 
melanin/PDA. Inspired by nature, we provide a new system that side-steps the main 
drawbacks of melanin and PDA and thus could extend the applicability of these potent 
macromolecules. Furthermore, the chemical versatility of polymersomes and their 
numerous possibilities for functionalization greatly extend the range of applications 













6. Overall conclusions and 
outlook 
 
Inspired by biological structures and processes, we engineered different synthetic 
systems hosting relevant biomolecules to obtain superior bio-hybrid nanomaterials 
with desired functions/interactions with cells or organisms that target specific 
biomedical applications. In this thesis, combinations of the following four strategies 
were adopted in producing innovative bio-hybrid compartments: 1) using polymers 
that easily self-assemble and enable the incorporation of membrane proteins, 2) 
selecting appropriate enzymes with desired activity, 3) choosing efficient 
reactions/appropriate biomolecules for the functionalization of the polymersomes 
and 4) segregating different active compounds in different compartments. 
Short-length PDMS-PMOXA di-block co-polymers were chosen as the synthetic 
building block of nanocompartments as they rapidly formed polymersomes within a 
wide range of assembly conditions. Tunability was an important feature, not only to 
accelerate polymersome production, which is beneficial for translational 
applications, but also to create conditions necessary for the incorporation and proper 
function of biomolecules within the polymeric vesicles.  
We established a therapeutic nanocompartment encapsulating active Dopa 
decarboxylase (DDC) which is a relevant enzyme in view of the treatment of 
atherosclerosis. To go a step further towards theranostic applications, the therapeutic 
catalytic compartments were coupled to imaging polymersomes by hybridization of 
complementary DNA strands present on the surface of the respective polymersomes, 
which also conferred cell attachment properties upon the theranostic polymersome 
clusters. The resulting dual-functional bio-hybrid system enabled cell imaging and 
induced relevant cell response via on-site and on-demand production of dopamine. 
This is the first time that co-localized therapeutic and imaging functions were 
achieved by clustering two types of nanocompartments. Importantly, the segregation 
of different modalities enabled to individually adapt the conditions of polymersome 





abolishing their function. The short lifetime of the encapsulated enzyme (DDC) and 
the non-specific cell attachment are the main limitations of this system. However, as 
these clusters are tunable, the incorporated enzymes and targeting agents could be 
modified to provide a dual-functional system aimed at other applications. 
By a similar catalytic compartment layout, we developed an imaging system with a 
large potential in pre-clinical applications. Gaussia Luciferase was encapsulated 
inside bio-hybrid nanocompartments to deliver a powerful and long-lasting light 
signal. This is the first example where the modulation of enzyme kinetics by altering 
the access of substrate to the confined enzyme is beneficial to imaging applications. 
Our bioluminescent system was able to produce detectable light signals in a cellular 
environment and was capable to cross biological tissues, corroborating its strong 
potential for application. The biodistribution and clearance of these polymersomes 
remain to be assessed to fully appreciate the applicability of such system for in vivo 
imaging. The particular application could be varied via surface functionalization of 
these polymersomes with targeting agents, e.g., to target and image tumours. 
Another kind of catalytic bio-hybrid system was developed to mimic native 
melanosomes, with the objective of providing a novel treatment approach for Vitiligo, 
Albinism and for reducing the risk of skin cancer. Melanin and polydopamine (PDA) 
precursors L-DOPA and dopamine, respectively, were encapsulated in polymersomes 
together with melanogenic Tyrosinase. The fast self-assembly of a selected polymer 
into vesicles was exploited to encapsulate the corresponding precursors before their 
polymerization into melanin/PDA. The polymersome-based system is currently the 
only example of melanin/PDA encapsulation inside synthetic nanocompartments. 
The polymeric membrane enabled to overcome the main downsides of conventional 
melanin/PDA-based nanoparticles: by curbing melanin/PDA production, the 
melanosome mimics exhibited decreased cytotoxicity and enhanced colloidal 
stability while maintaining UV-absorption properties, thereby demonstrating their 
potential for cell photoprotective applications. The relatively low cell uptake and 
resulting perinuclear aggregation of our polymersomes remain their main 
limitations, which could be solved with the functionalization of their surface with cell-
penetrating agents (e.g., peptides) and nucleus targeting agents. 
Taken together, the use of a short length block copolymer was critical parameter in 





compartments, which in turn is key to incorporating diverse biomolecules and thus, 
key to expanding biomedical applicability. The combination of the different strategies 
resulted in catalytic bio-hybrid systems that lay the grounds for new kinds of 
biomedical applications, for example a theranostic approach for the treatment of 
atherosclerosis, bioluminescent imaging systems for pre-clinical studies and 
photoprotective solutions to prevent skin cancer. In-depth in vivo studies are now 


























7.1 Chapter 3 
7.1.1 Materials  
DBCO-ss-DNA sequences were purchased from IBA Lifesciences (Göttingen, 
Germany). DDC was purchased from Biotechne (Zug, Switwerland). Dulbecco’s PBS 
was purchased from BioConcept (Allschwill, Switzerland). L-DOPA (levodopa), 
dopamine hydrochloride, pyridoxal 5’-phosphate monohydrate, BSA, reduced L-
glutathione, diethanolamine, L-homoarginine, magnesium chloride, and p-
nitrophenyl phosphate were obtained from Sigma-Aldrich (St. Louis, USA). N-Octyl-
β-D-glucoside was purchased from Anatrace (Maumee, USA). The fluorescent probes 
Atto-488 and DY-633 were purchased from ATTO-TEC GmbH (Siegen, Germany) and 
Dyomics GmbH (Jena, Germany), respectively. All compounds and solvents were used 
as received.  
 
7.1.2 Synthesis of PDMS22-PMOXA8-OEG3-N3 
PDMS22-PMOXA8 with a hydroxyl functional group (PDMS22-PMOXA8-OH) was 
synthesized accordingly to the well-established protocol of our research group.34 
PDMS22-PMOXA8 with azide as the end functional group (PDMS22-PMOXA8-N3) was 
synthesized accordingly our recently published procedure122 with slight modifications. 
Briefly, PDMS22-PMOXA8-OH (350 mg) was first dissolved in 10 mL anhydrous 
chloroform at RT, then succinic anhydride (30 mg,), 4-dimethylaminopyridine (5 mg) 
and TEA (30 μL) were added successively. The mixture was deoxygenated by means of 
three vacuum-argon cycles, and then stirred for another 72 h at room temperature 
under Ar. Ultrafiltration afforded colorless PDMS22-PMOXA8 with a carboxylic acid 
end group (PDMS22-PMOXA8-COOH) (yield: 300 mg, 86%). This PDMS22-PMOXA8-
COOH (300 mg) was dissolved in anhydrous chloroform at room temperature, then 
11-azido-3,6,9-trioxaundecan-1-amine (50 mg), N,N'-dicyclohexylcarbodiimide (46 





deoxygenated three times, then stirred at 30 rpm for another 48 h at RT. Ultrafiltration 
afforded colorless PDMS22-PMOXA8-N3 (yield: 220 mg, 73%). 
 
7.1.3 Formation of the different polymersomes 
Rapid formation of empty PDMS22-PMOXA8-OEG3-N3 polymersomes: PDMS22-
PMOXA8-OEG3-N3 block copolymers were dissolved in ethanol to yield a stock 
solution with a concentration of 10 mg/mL. 400 µL of this solution was transferred 
into a 5 mL round-bottomed flask, and dried in a rotary evaporator (170 mbar, 40 ˚C, 
75 rpm). 1 mL of PBS was added to the residue, and the flask was gently shaken with 
stirring bar for less than 1 min at RT. The resulting solution was extruded 15 times 
through a polycarbonate (PC) membrane with a 200 nm diameter pore size on an 
Avanti mini-extruder (Avanti Polar Lipids, Alabama, USA) to unify the size of the 
polymersomes. 
 
Preparation of HRP-Ncomp: PDMS22-PMOXA8-OEG3-N3 stock solution (200 µL, 10 
mg/mL) was transferred into a 5 mL round-bottomed flask, and dried on a rotary 
evaporator (170 mbar, 40 ˚C, 75 rpm). HRP solution (100 μL, 0.2 mg/mL) containing 
0.1 wt% BSA with either PBS (100 µL) or OmpF (100 μL, 0.1 mg/mL or 0.2 mg/mL) 
was added to the residue, resulting in a final concentration of 0.16 mg/mL of HRP, 4 
mg/mL of PDMS22-PMOXA8-OEG3-N3 and 0 mg/mL, 0.02 mg/mL, and 0.04 mg/mL 
of OmpF. The flask was gently shaken with a stirring bar for less than 10 seconds at 
room temperature. The resultant HRP-Ncomp was extruded the same way as 
described for the empty polymersomes. Free HRP was removed by means of SEC, 
eluted with PBS.  
 
Preparation of DDC-Ncomp: A solution of PDMS22-PMOXA8-OEG3-N3 polymer 
dissolved in ethanol (600 µL, 10 mg/mL) was transferred into a 5 mL round-bottomed 
flask, and dried on a rotary evaporator (170 mbar, 40 ˚C, 75 rpm). In parallel, freshly 
thawed DDC (20 µg) was dissolved in 0.1 wt% BSA in PBS (1 mL) and pyridoxal 
phosphate in PBS (50 µL, 5 mM). The mixture was gently stirred at 4°C for 20 min. 
The thin polymer film was rehydrated with this DDC solution (522 µL) mixed with 
dialyzed OmpF solution (78 µL, 0.8 mg/mL to give the same polymer/OmpF ratio as 





stirred 3 hours at 4 °C, and then extruded 15 times through a PC membrane with a 200 
nm diameter pore size under sterile conditions to unify the size of the polymersomes.  
 
Preparation of Dye-Ncomp: A stock solution of PDMS22-PMOXA8-OEG3-N3 block 
copolymer was obtained by dissolution of the polymer in ethanol (600 µL, 10 mg/mL), 
and transferred to a round-bottomed flask, followed by drying on a rotary evaporator 
(170 mbar, 40 ˚C, 75 rpm). The resultant thin polymer film was rehydrated by adding 
a solution of DY-633 (600 µL, 0.2 mM in PBS). The product was stirred overnight at 
room temperature before being extruded in the same way as described for DDC-
Ncomp.  
 
7.1.4 Conjugation of DNA with empty polymersomes 
Empty polymersomes (4 mg/mL) were mixed with 1 eq. per azide group of ssDNAa or 
spacer-ssDNAa labelled with DY-633 (0.5 mM in water). The reaction was carried out 
overnight at 4 °C. Free DNA was removed by size exclusion chromatography (SEC) 
eluted with PBS. 
 
7.1.5 Conjugation of DNA and clusters formation 
 Extruded DDC-Ncomp and Dye-Ncomp (500 µL each) were mixed with 1 eq. per azide 
group of ssDNA/spacer-ssDNAa (0.5 mM in water) overnight (4 °C) and 
ssDNAb/spacer-ssDNAb (0.5 mM in water) overnight (37 °C), respectively. The two 
solutions were purified by means of SEC to remove free DNA, under sterile conditions, 
and cold PBS. The volumes of purified polymersomes solutions were adjusted to 
obtain a polymer concentration of 2 mg/mL. To prepare clusters, the two solutions 
were mixed (1:1) and incubated at 20 °C for 20 min. The resulting cluster solution was 
used immediately. 
 
7.1.6 Physical characterization of polymersomes and clusters 
Transmission electron microscopy (TEM): A 5 μL aliquot of polymersomes or 
polymersome clusters (0.1 mg/mL) was absorbed on 400 mesh square copper grids. 





of nanostructures was obtained with a transmission electron microscope (Philips 
CM100) at an accelerating voltage of 80 kV.  
 
Dynamic light scattering (DLS): The apparent diameter DH values of polymersomes 
and polymersome clusters were obtained on a Zetasizer Nano ZSP (Malvern 
Instruments Inc., UK) at 25 °C. 400 μL of each sample solution (0.2 mg/mL final 
concentration) was added to a cuvette and subjected to 11 runs repeated three times. 
The measured angle was 173° and the data was analyzed by intensity distribution. To 
examine the kinetics of polymersome cluster formation, measurements were run for 3 
min with a 2 min interval.  
 
Zeta potential measurements: The electrophoretic mobility of vesicles in solution was 
determined by means of laser Doppler velocimetry and phase-analysis light-scattering 
measurements. A Malvern Zetasizer Nano ZSP (Malvern Instruments Inc, UK) with a 
633 nm wavelength laser was used for all measurements. The vesicle samples (0.2 
mg/mL) were measured in PBS with five repeat measurements per sample. All 
experiments were run at 25 °C. 
 
Static light scattering (SLS): Multi-angle dynamic light scattering (DLS) and static 
light scattering (SLS) were performed on a setup from LS Instruments (Switzerland), 
equipped with a 21 mW He-Ne laser (λ = 632.8 nm) for scattering angles from 30° to 
150° at 25 °C. All samples were diluted in order to suppress multiple scattering. 
Second-order cumulant analysis for various angles was performed to obtain the 
hydrodynamic radius (Rh). The radius of gyration (Rg) was obtained from the SLS 
data using a Guinier plot.  
 
Fluorescence Correlation Spectroscopy (FCS): FCS was performed on a Zeiss LSM 
880 microscope (Zeiss LSM 880, inverted microscope ZEISS Axio Observer, Carl 
Zeiss, Jena, Germany). A 488 nm argon laser was used to excite ssDNA labelled with 
Atto-488 and the conjugated Ncomp. The laser beam was passed through main beam 
splitter MBS488 and signals were detected in the range of 500-532 nm. A 633 nm 
HeNe laser, was used for DY-633 labelled ssDNA and the conjugated Ncomp. The laser 





range of 650-740 nm, the pinholes were adjusted to maximize the count rate using the 
corresponding free dye in PBS. The sample volume was 15 μL. Fluorescence 
fluctuations over time were recorded for 30 x 10 s. The raw data was processed and 
analyzed using Zeiss software. Autocorrelation curves were fitted to a two-component 
model (Equation S1).  



























1/2]    (1) 
Where 𝐺2𝑐𝑜𝑚𝑝(𝜏) is the two-component autocorrelation function, N is the number of 
particles, S is the structural parameter, 𝑇𝑡𝑟𝑖𝑝 is the fraction of fluorophores in the triplet 
state, 𝜏𝑡𝑟𝑖𝑝 is the corresponding triplet time, f1 and f2 are the fractions of the particles 
of the corresponding component 1 or 2, and 𝜏𝐷1 and 𝜏𝐷2 are the diffusion times of the 
corresponding component 1 or 2. 
 
7.1.7 Estimation of DDC encapsulation efficiency 
 Polymersomes encapsulating BSA (BSA-Ncomp) were formed under the same 
conditions described above, but using BSA in place of DDC and using PBS only 
(without further 0.1 wt% BSA). The concentration of non-encapsulated BSA was 
determined from the fraction of free BSA present in the solution after SEC purification 
of BSA-Ncomp. Polymersomes rehydrated under the same conditions but without BSA 
were also formed and purified for use as a blank. After UV-vis (280 nm) absorbance 
measurements using a NanoDrop 2000 spectrophotometer (Thermofisher) in BSA 
mode, we determined the amount of BSA molecules encapsulated in polymersomes. 
We calculated the difference between the total amount of BSA used for film 
rehydration and the amount of non-encapsulated BSA, which gave a number of 
1.79*1013 ± 4.71*1012 molecules of BSA encapsulated. In parallel, the concentration of 
vesicles (1.3*1012 vesicles/mL) was determined via single nanoparticle tracking 
analysis (NTA) using a NanoSight NS300 instrument from Malvern Panalytical 
(Malvern, United Kingdom). We divided the number of encapsulated BSA molecules 
by the number of vesicles in our solution (600 µL), obtaining a value of 23.01 ± 6.03 
BSA molecules encapsulated per vesicle. Assuming similar numbers of BSA and DDC, 





7.1.8 Expression and extraction of OmpF 
 Wild-type OmpF was obtained according to a previously reported protocol,126 with a 
few modifications: bacteria were grown at 30 °C for 6 h on Terrific Broth (TB) (Difco, 
U.S.A.), and all ultracentrifugations were performed at room temperature. 
 
7.1.9 Activity determination of catalytic nanocompartments: 
Activity of model HRP-Ncomp: HRP-Ncomp (10 μg/mL) was incubated in the 
presence of H2O2 (10 µM) in a 96-well black plate (Thermo Fisher Scientific), before 
the addition of Amplex Red (1 µM) to give a final volume of 200 µL/well. The change 
of fluorescence (excitation 570 nm / emission 595 nm) after the addition of Amplex 
Red was recorded immediately using a Spectramax M5 microplate reader (Molecular 
Devices, USA).  
 
Activity of DDC-Ncomp: 80 µL of purified 1 mg/mL of DDC-Ncomp, DDC-Ncomp 
functionalized with ssDNA, theranostic clusters or DDC-Ncomp without OmpF was 
mixed with 10 µL of L-OPA (5 mM in water), 10 µL of reduced glutathione (20 mM in 
PBS) and 2 µL of pyridoxal phosphate (5 mM in water), and incubated 24 h at 37 °C. 
Then, each solution was purified by SEC to remove the polymersomes, and analysed 
by reverse-phase HPLC to detect the presence of dopamine. The percentage 
conversion of L-DOPA to dopamine was calculated from the areas of the 
corresponding peaks: for every sample, the area of the dopamine peak is multiplied by 
100 and divided by the sum of the areas of the dopamine and L-DOPA peaks. This 
approach was chosen to avoid potential errors in the assessment of L-DOPA and 
dopamine concentrations due to sample dilution during SEC purification, which was 
required to prevent injection of vesicles into the HPLC. The retention times for 
dopamine and L-DOPA were determined using a reverse-phase Shimadzu HPLC 
(Reinach, Switzerland). A 20-min method using water containing 0.1% TFA as a 
mobile phase at 0.5 mL/min though an analytical Chromolith performance RP-18e 
column (Merck, Schaffhausen, Switzerland) separated dopamine (10.1 min) and L-
DOPA (11.8 min). At equal concentrations, the peaks corresponding to dopamine and 





7.1.10  Cell culture 
 The stable double-transgenic cell line HEKREWARD was cultured in Dulbecco’s 
modified Eagle’s medium GlutaMAXTM-I (DMEM-GlutaMAX, Gibco Life Sciences) 
supplemented with 10% FCS (BioConcept), 100 units/mL penicillin and 100 µg/mL 
streptomycin (Sigma Aldrich). After 14 days, the polyclonal population was selected 
according to reported methodology.119 Cells were maintained at 37 ºC in a humidified 
atmosphere of 5% CO2 in air.  
 
7.1.11 Cellular attachment and imaging 
 Freshly trypsinized cells were seeded at a density of 60 000 cells per well, in 8-well 
ibidi collagen IV-coated plates. After 24 h, the cell culture medium was removed and 
replaced with 130 µL Opti-MEM (Gibco Life Sciences) live cell imaging medium. Next, 
cells were dosed with polymersome clusters (70 µL, 2 mg/mL) and imaged by CLSM 
at intervals for 2 h. CLSM measurements were performed on a laser-scanning 
microscope ZEISS LSM 880 inverted microscope (ZEISS Axio Observer, Carl Zeiss, 
Germany).  
For visualizing polymersome clusters in the presence of cells, the two Ncomps 
were loaded with Atto-488 and DY-633, respectively, and two lasers, a 488 nm argon 
laser and a 633 nm HeNe laser, were used. The beams were passed through MBS488 
and MBS488/561/633 filters, respectively, and focused onto the sample through a 
water immersion objective (C-Apochromate 40x/1.2W korr FCS M27). Detection was 
done at 505-555 nm and 650-740 nm, respectively. For polymersome clusters formed 
from DDC-Ncomp and dye-Ncomp, only the 633 nm HeNe laser was utilized.  
For the 24 hour time points, freshly trypsinized cells were seeded at a density 
of 30 000 cells per well in 8-well ibidi collagen IV-coated plates. After 24 h, cells were 
treated with the polymersome clusters as previously described. After a further 24 h 
incubation, the cells were washed 3x with Opti-MEM prior to CLSM imaging. Images 
were processed using Fiji ImageJ and colocalization analysis based on Pearson’s 
coefficient of colocalization was performed using the JACoP plugin. 3D rendering of z-






7.1.12 Cell activation by DDC-Ncomp and theranostic clusters 
 Cells were plated in a 96-well plate (100 µL/well of 10 000 cells) and incubated 
overnight. The next day, 75 µL of media was removed and 75 µL of free DDC (different 
concentrations) or 1 mg/mL of DDC-Ncomp w/o OmpF, DDC-Ncomp, ssDNA-
functionalized DDC-Ncomp or theranostic clusters was added to the wells. Wells were 
filled with 100 µL of media containing L-DOPA (10 µM) and pyridoxal phosphate (12.5 
µM) and incubated for 3 days. Then, the SEAP level was assayed using a standard p-
nitrophenyl phosphate–based absorbance method as previously described.201 In brief, 
the cell supernatant corresponding to each condition was assayed by recording the rate 
of production of p-nitrophenol from the SEAP substrate p-nitrophenyl phosphate, 
calculated from the absorbance at 405 nm. The amount of SEAP expressed under each 
condition was calculated using the slope of the kinetic curve of p-nitrophenol 
production.  
 
7.2 Chapter 4 
7.2.1 Materials 
Gaussia Luciferase was purchased from Enzo life sciences (Lausen, Switzerland). 
Water-soluble coelenterazine was purchased from Nanolight technologies (Pinetop, 
USA). Dulbecco’s PBS was purchased from BioConcept (Allschwill, Switzerland). N-
Octyl-β-D-glucoside was purchased from Anatrace (Maumee, USA). All compounds 
and solvents were used as received. 
 
7.2.2 Synthesis of PDMS25-PMOXA10  
Synthesis of monocarbinol-functionalized poly(dimethyl siloxane) (PDMS25-OH). All 
reactions were conducted under argon atmosphere in dried glassware. 
Hexamethylcyclotrisiloxane (D3) (100 g, 0.450 mol) was added to a 250 mL one-neck 
round-bottom flask and dried over calcium hydride at 75 °C. After two days, D3 was 
distilled under vacuum into a 250 mL three-neck round bottom flask with a yield of 
90.32 g (0.406 mol, 13 eq). Dried cyclohexane (150 mL) was added, followed by 





After stirring for 4 h, dried tetrahydrofuran (15 mL) was added and the reaction was 
left stirring for 38.5 h at room temperature. The polymerization was quenched by 
addition of dimethylchlorosilane (9.46 g, 11.1 mL, 100 mmol, 3.2 eq). After 4 h of 
stirring, the solution was filtered through a glass frit to remove the precipitated lithium 
chloride salt. Then, the solvents were evaporated using a rotary evaporator and 
unreacted D3 was removed via subsequent vacuum distillation. The remaining 
hydride-terminated PDMS25-H (58.35 g, 31.5 mmol) was dissolved in dried toluene 
(80 mL), followed by the addition of 2-allyloxyethanol (3.76 g, 3.94 mL, 33.1 mmol) 
and platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex solution (Pt(dvs), 
in xylene, 35.9 µL). The flask was equipped with a reflux condenser and the solution 
stirred at 110 °C overnight. Afterwards, toluene was removed using a rotary evaporator 
and the crude monocarbinol-functionalized PDMS25-OH was dissolved in 
dichloromethane (100 mL). Activated charcoal was added, the solution stirred for 30 
min and filtered through Celite S. Finally, the solvent was evaporated to yield a 
colorless PDMS25-OH oil (55.07 g, Mn = 2000 g/mol, 27.5 mmol). PDMS25-H and 
PDMS25-OH were characterized by 1H-NMR. 
Synthesis of poly(dimethyl siloxane)-block-poly(2-methyl-2-oxazoline) (PDMS25-
b-PMOXA10). All reactions were conducted under argon atmosphere in dried 
glassware. PDMS25-OH (10 g, 4.89 mmol, 1 eq) was added to a 250 mL three-neck 
round-bottom flask and dried overnight at 100 °C under vacuum. After addition of 
dried hexane (85 mL) and dried and distilled trimethylamine (0.643 g, 0.886 mL, 6.36 
mmol, 1.3 eq), the solution was cooled with an ice/sodium chloride/acetone bath and 
stirred for 15 min. Then trifluormethanesulfonic anhydride (triflic anhydride, 1.66 g, 
0.987 mL, 5.87 mmol, 1.2 eq) in hexane (15 mL) was added dropwise over 30 min 
under cooling. After 4 h stirring, the solution was filtered through a glass frit under 
inert atmosphere in order to remove the precipitated triflate salt. The resulting triflate-
activated PDMS (PDMS25-OTf) was obtained after evaporation of the solvent. 
Subsequently, dried ethylacetate (100 mL) and 2-methyl-2-oxazline (4.58 g, 4.56 mL, 
53.8 mmol, 11 eq) were added and the solution was heated to 40 °C. After 63 h, the 
solution was cooled to room temperature and water (5 mL) and trimethylamine (5 mL) 
were added in parallel to quench the reaction. After 6 h, the solvents were evaporated 
using a rotary evaporator. For purification, the crude copolymer was dissolved in 300 
mL methanol and centrifuged (4000 rpm, 1664 rcf, 10 min) in order to remove the 





round bottom flask, the solvent was evaporated. Subsequently, the copolymer (13.91 
g) was dissolved in a 1:1 mixture of ethanol and water and dialysed against 
ethanol:water (1:1, 2 L in total) with 5 changes over two days, followed by a last dialysis 
step against water (2 L). The resulting copolymer precipitate was lyophilized. The 
purified copolymer (11.82 g) was not able to undergo self-assembly into vesicular 
structures. Therefore, it was extracted in a 1:1 mixture of methanol and hexane (each 
200 mL). The solvent from the bottom methanol-enriched phase was evaporated and 
the purified, PDMS25-b-PMOXA10 was obtained as a slightly yellow gel (10.74 g, Mn = 
2850 g/mol, 3.77 mmol). PDMS25-OTf and PDMS25-b-PMOXA10 where characterized 
by 1H-NMR. 
 
7.2.3 Preparation of polymersomes 
Preparation of GLuc Ncomp: PDMS25-PMOXA10 block copolymers were dissolved in 
ethanol to yield a stock solution with a concentration of 10 mg/mL. 600 µL of this 
solution was transferred into a 5 mL round-bottom flask and dried in a rotary 
evaporator (170 mbar, 40 ˚C, 75 rpm). The resulting thin polymer film was rehydrated 
with a solution composed of 322 µL PBS, 200 µL Gaussia Luciferase (GLuc; 0.1 
mg/mL in PBS) and 78 µL dialyzed OmpF solution (0.8 mg/mL) which yields the 
polymer/OmpF ratio previously used for the preparation of PDMS-PMOXA catalytic 
polymersomes153. The resulting solution was stirred overnight at 4 °C, and then 
extruded (under sterile conditions) 15 times through a polycarbonate (PC) membrane 
with a 200 nm diameter pore size using an Avanti mini-extruder (Avanti Polar Lipids, 
Alabama, USA) to unify the size of the polymersomes. The unencapsulated enzymes 
were removed by size-exclusion chromatography (SEC) eluted with PBS. 
 
Preparation of control polymersomes: Control polymersomes were prepared as 
described for GLuc Ncomp (600 µL of 10 mg/mL PDMS25-PMOXA10 solution; 
overnight stirring at 4 °C) with the following modifications: empty polymersomes were 
rehydrated with PBS only and GLuc Ncomp without OmpF were rehydrated with a 
solution of GLuc and a solution of dialyzed 3 % OG (to match the traces of OG ≃ 0.05 





7.2.4  Physical characterization of polymersomes 
Dynamic light scattering (DLS): The apparent diameter DH values of polymersomes 
were determined on a Zetasizer Nano ZSP (Malvern Instruments Inc., UK) at 25 °C at 
an angle of 173°. Each sample was diluted with PBS to 0.2 mg/mL final concentration. 
A cuvette was filled with 500 μL sample and subjected to 11 measurement runs with 
three repetitions.  
 
Static light scattering (SLS): Multi-angle dynamic light scattering (DLS) and static 
light scattering (SLS) were performed on a setup from LS Instruments (Switzerland), 
equipped with a 21 mW He-Ne laser (λ = 632.8 nm) for scattering angles from 30° to 
150° at 25 °C. All samples were diluted in order to avoid multiple scattering. Second-
order cumulant analysis for various angles was performed to obtain the hydrodynamic 
radius (Rh). The radius of gyration (Rg) was obtained from the SLS data using a MIE 
fit.159 
 
Transmission electron microscopy (TEM): 5 μL aliquots of polymersomes (0.1 
mg/mL) were adsorbed to 400 mesh square copper grids. Excess liquid was blotted 
and grids were negatively stained with 2% uranyl acetate. Micrographs of 
nanostructures were recorded on a Philips CM100 transmission electron microscope 
at an accelerating voltage of 80 kV.  
 
7.2.5  Expression and extraction of OmpF  
Recombinant wild-type OmpF was produced according to a previously reported 
protocol,63 with the following modifications: Transformed E.coli were grown for 6 h at 
30 °C in Terrific Broth (TB; Difco, U.S.A.), and ultracentrifugation was performed at 
room temperature.  
 
7.2.6  Estimation of GLuc encapsulation efficiency 
 The concentration of non-encapsulated GLuc was determined from the fraction of free 





polymersomes with OmpF formed under the same conditions as GLuc Ncomp (but 
without GLuc) were used as a blank. After UV-vis (280 nm) absorbance measurements 
using a NanoDrop 2000 spectrophotometer (Thermofisher), we determined the 
amount of GLuc molecules encapsulated for 1mL of polymersomes (1.21*1013 ± 
5.52*1012) by calculating the difference between the total amount of GLuc used for film 
rehydration and the total amount of enzyme that was not encapsulated. In parallel, the 
concentration of vesicles (1.7*1012 vesicles/mL) was determined via single 
nanoparticle tracking analysis (NTA) using a NanoSight NS300 instrument from 
Malvern Analytical (Malvern, United Kingdom). The number of encapsulated GLuc 
molecules was divided by the number of vesicles, obtaining a value of 7 ± 3 GLuc 
molecules encapsulated per vesicle. An estimation of the percentage of GLuc 
encapsulated has been calculated to be 12 ± 5 %. After SEC purification, the 
concentrated GLuc Ncomp solution (2 mg/mL) was obtained, corresponding to a 
concentration of GLuc of 0.80 µg/mL. 
 
7.2.7   Activity of GLuc and GLuc Ncomp in PBS 
 GLuc Ncomp, free GLuc enzyme and control polymersomes were assayed using a 
spectrophotometer equipped with an injector (SpectraMax ID3 microplate reader, 
Molecular Devices, U.S.A.) in luminescence mode using black 96-well plates. 50 µL 
GLuc Ncomp (1 mg/mL), control polymersomes (1 mg/mL), or free GLuc enzyme (0.4 
µg/mL, corresponding to 1 mg/mL of GLuc Ncomp) was added to each well. 
Subsequently, 50 µL/well of a freshly prepared coelenterazine substrate (80 µM in 
PBS) was added by means of the automatic injector to ensure the direct recording of 
luminescence. To determine the kinetics, luminescence was measured every 30 
seconds for 1 hour.  
 
7.2.8   Activity of GLuc and GLuc Ncomp in cell supernatant 
MCF-7 cells were seeded in a 96-well plate (3000 cells in 100 µL /well) and cultured 
overnight at 37°C. Then, 50 µL of the cell supernatant was removed and replaced by 
50 µL of fresh medium and 100 µL of GLuc Ncomp (2 mg/mL), free GLuc (0.8 µg/mL), 





supernatant was collected and assayed for luminescence production as described 
above. 
 
7.2.9  Stability of GLuc and GLuc Ncomp 
 After storage of GLu Ncomp, GLuc Ncomp without OmpF and free GLuc for 3, 7 and 
14 days at 4 °C or 37 °C in PBS or cell medium, samples with a consistent enzyme 
concentration of 0.40 µg/mL were assayed for luminescence production in the same 
manner as described above. The activity recorded on the day of polymersome 
preparation (Day 0) in PBS or cell medium was set to 100%. The activity after different 
time periods of storage was determined in comparison to the activity of Day 0. 
Luminescence production at the time point where the luminescence signal is the 
highest (t = 10 min for GLuc Ncomp and t = 0 for free GLuc enzymes) was used to 
compare the activity of GLuc over time of storage.  
 
7.2.10  Cell culture  
 MCF-7 (epithelial breast cancer, human; ATCC, HTB-22) were routinely cultured in 
Eagle's Minimum Essential Medium (EMEM, Gibco Life Sciences) supplemented with 
10% fetal bovine serum (BioConcept), 100 units/mL penicillin and 100 µg/mL 
Streptomycin (Sigma Aldrich). Cells were maintained in a humidified atmosphere at 
37 oC and 5% CO2. 
 
7.2.11  Cell viability assay (MTS) 
 CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, Invitrogen) was 
used to determine cell viability. In accordance with the supplier's protocol, MCF-7 cells 
were seeded at a concentration of 3000 cells/well in a 96 well plate. After 24 h, 50 µL 
of medium was removed and replaced by 50 µL of fresh medium and 100 µL of GLuc 
Ncomp (2 mg/mL), free GLuc, or control PBS. The cells were incubated in the presence 
of GLuc Ncomp, free GLuc or PBS control for 3 more days in a humidified atmosphere 





at 490 nm was measured after 2 h at 37 °C using a Spectramax plate reader. The data 
was normalized to PBS treated control cells after background absorbance removal.  
 
7.2.12  In vivo Bioluminescence Imaging 
BALB/c mice have been intravenously injected (IV) with 100 μL of 2 mg/mL GLuc 
Ncomp or GLuc Ncomp without OmpF, in the tail vein. After 30min, 100 μl of 1 mg/mL 
coelenterazine was injected in the tail vein. Mice were anesthetized and placed in the 
imaging chamber of a IVIS Lumina In vivo Imaging system (PerkinElmer) and 
bioluminescence intensity has been recorded for 20 min and summed up. The number 
of mice was set to 3 per group, but the difficult technical procedure of double IV 
injection in the tail vein resulted in only one mice per group with successful double 
injection. Coelenterazine is usually injected retro-orbitally but animal law protection 
is Switzerland do no permit this procedure. 
 
7.3 Chapter 5 
7.3.1 Materials 
All compounds were used as received. Tyrosinase from Mushroom, Dopamine (3,4-
dihydroxyphenethylamine) and L-DOPA (3,4-dihydroxy-L-phenylalanine) were 
purchased from Sigma (Buchs, Switzerland). 
 
7.3.2 Synthesis of PDMS24-PMOXA12  
Poly(dimethyl siloxane)-block-poly(2-methyl-2-oxazoline) (PDMS24-b-PMOXA12) 
was synthesized following a previously reported protocol.34 Briefly, hydroxyl-
terminated PDMS (PDMS-OH) was obtained after anionic ring-opening 
polymerization of hexamethylcyclotrisiloxane and end group modification with 2-
allyloxyethanol. Subsequently, activation of PDMS-OH with trifluormethanesulfonic 
anhydride was followed by cationic ring-opening polymerization of MOXA monomer. 
After quenching the polymerization with water and purification via dialysis, the final 





2400 g/mol) was obtained from 1H NMR spectroscopy, whereas a dispersity of 1.16 
was measured via gel permeation chromatography.  
 
7.3.3 Preparation of polymersomes 
Preparation of Melanin/PDA polymersomes: PDMS24-b-PMOXA12 block copolymers 
were dissolved in ethanol to yield a stock solution with a concentration of 10 mg/mL. 
600 µL of this solution was transferred into a 5 mL round-bottom flask and dried in a 
rotary evaporator (170 mbar, 40 ˚C, 75 rpm). The resulting thin polymer film was 
rehydrated with a solution composed of 300 µL of Dopamine or L-DOPA (2 mM in 
PBS) and 300 µL Tyrosinase (6 µM in PBS). The resulting solution was stirred for 30 
min at 4 °C, and then extruded (under sterile conditions) 15 times through a 
polycarbonate (PC) membrane with a 200 nm diameter pore size using an Avanti mini-
extruder (Avanti Polar Lipids, Alabama, USA) to unify the size of the polymersomes. 
The unencapsulated compounds were removed by size-exclusion chromatography 
(SEC) eluted with cold PBS. 
 
Preparation of control polymersomes: Control polymersomes were prepared as 
described for Melanin/PDA polymersomes (600 µL of 10 mg/mL PDMS24-b-PMOXA12 
solution; 30 min stirring at 4 °C) with the following modifications: empty 
polymersomes were rehydrated with PBS only; Atto-488 polymersomes were 
rehydrated with 0.2 mM of Atto-488 in PBS, Dopamine or L-DOPA polymersomes 
were rehydrated with 300 µL of PBS and 300 µL of Dopamine or L-DOPA (2 mM), 
respectively. 
 
7.3.4 Physical characterization of polymersomes 
Dynamic light scattering (DLS): The apparent diameter DH values of polymersomes 
were determined on a Zetasizer Nano ZSP (Malvern Instruments Inc., UK) at 25 °C at 
an angle of 173°. Each sample was diluted with PBS to 0.1 mg/mL final concentration. 
A cuvette was filled with 500 μL sample and subjected to 11 measurement runs with 






Zeta potential measurements: The electrophoretic mobility of vesicles in solution was 
determined by means of laser Doppler velocimetry and phase-analysis light-scattering 
measurements. A Malvern Zetasizer Nano ZSP (Malvern Instruments Inc, UK) with a 
633 nm wavelength laser was used for all measurements. The vesicle samples (0.1 
mg/mL) were measured in PBS with five repeat measurements per sample. All 
experiments were run at 25 °C. 
 
Static light scattering (SLS): Multi-angle dynamic light scattering (DLS) and static 
light scattering (SLS) were performed on a setup from LS Instruments (Switzerland), 
equipped with a 21 mW He-Ne laser (λ = 632.8 nm) for scattering angles from 30° to 
150° at 25 °C. All samples were diluted in order to avoid multiple scattering. Second-
order cumulant analysis for various angles was performed to obtain the hydrodynamic 
radius (Rh). The radius of gyration (Rg) was obtained from the SLS data using a MIE 
fit.159 
 
Transmission electron microscopy (TEM): 5 μL aliquots of polymersomes (0.1 
mg/mL) were adsorbed to 400 mesh square copper grids. Excess liquid was blotted 
and grids were negatively stained with 2% uranyl acetate. Micrographs of 
nanostructures were recorded on a Philips CM100 transmission electron microscope 
at an accelerating voltage of 80 kV.  
 
7.3.5 Estimation of Tyrosinase encapsulation efficiency 
 Tyrosinase polymersomes were produced via film rehydration using 300 μL of PBS 
and 300 μL of Tyrosinase (6 µM) in the same conditions as for Melanin/PDA 
polymersomes. The concentration of non-encapsulated Tyrosinase was determined 
from the fraction of free Tyrosinase present in the solution after SEC purification of 
Tyrosinase Ncomp. After UV-vis (280 nm) absorbance measurements using a 
NanoDrop 2000 spectrophotometer (Thermofisher), we determined the amount of 
Tyrosinase molecules encapsulated for 1 mL of polymersomes (1.69*1013) by 





rehydration and the total amount of enzyme that was not encapsulated. In parallel, the 
concentration of vesicles (2.1*1012 vesicles/mL) was determined via single 
nanoparticle tracking analysis (NTA) using a NanoSight NS300 instrument from 
Malvern Analytical (Malvern, United Kingdom). The number of encapsulated 
Tyrosinase molecules was divided by the number of vesicles, obtaining a value of 8 ± 
3 Tyrosinase molecules encapsulated per vesicle. An estimation of the percentage of 
Tyrosinase encapsulated has been calculated to be 9 ± 4 %. After SEC purification, the 
concentrated Melanin/PDA polymersomes solution (1 mg/mL) was obtained, 
corresponding to a concentration of Tyrosinase of 0.28 µM. 
 
7.3.6 Estimation of Dopamine and L-DOPA encapsulation efficiency 
 Control polymersomes enclosing only Dopamine or L-DOPA (see above) were used to 
assess the number of Dopamine and L-DOPA molecules per polymersome. The 
concentration of Dopamine of L-DOPA encapsulated in 1 mL of polymersomes (1 
mg/mL) was assessed via UV-vis (280 nm) absorbance (SpectraMax ID3 microplate 
reader, Molecular Devices, U.S.A.), by measuring the unencapsulated Dopamine/L-
DOPA obtained after purification of polymersomes.  In parallel, the concentration of 
vesicles (1.9*1012 vesicles/mL for Dopamine polymersomes and 1.9*1012 vesicles/mL 
for L-DOPA polymersomes) was determined via NTA. The total number of 
encapsulated molecules was divided by the number of vesicles, obtaining a value of 
3.8*104 ± 0.4*104 Dopamine molecules/vesicle and 4.4*104 ± 0.3*104 L-DOPA 
molecules/vesicle. Considering the initial concentration of Dopamine and L-DOPA 
used for film rehydration (1 mM), an estimation of the percentage of encapsulation has 
been calculated to be 13 ± 3 % for Dopamine and 11 ± 5 % for L-DOPA. The 
concentrated solutions (1 mg/mL) of Dopamine and L-DOPA polymersomes 
correspond to an estimated concentration of 0.11 mM and of 0.13 mM for Dopamine 
and L-DOPA, respectively. 
 
7.3.7 Adsorption of L-DOPA/Dopamine on the surface of polymersomes 
 Empty polymersomes (1 mg/mL) were mixed with L-DOPA/Dopamine (final 
concentration of 10 µM), with and without tyrosinase (final concentration of 30 nM) 





100 times lower concentrations than what was used form film rehydration of 
polymersomes. We aimed to reproduce the case figure of if only 1% of compounds was 
adsorbing on polymersomes’ surface or was not eliminated during purification, we 
would notice because it triggers aggregation of polymersomes. 
 
7.3.8 Melanin/PDA polymerization inside polymersomes 
 The polydopamine and melanin polymerization within polymersomes was followed 
up to 24 h days of incubation at 37 °C temperature, via UV-vis ( 250 – 700 nm) 
absorbance (SpectraMax ID3 microplate reader, Molecular Devices, U.S.A.). 200 µL 
of 1 mg/mL polymersomes (directly after their formation) was added in each well of a 
96-well microplate (UV-Transparent plates, Corning, USA) and triplicates were 
measured for each condition. The kinetics of formation of free polydopamine/melanin 
was not followed with this method as is rapidly led to the sedimentation of aggregates. 
 
7.3.9 Cell culture 
 HaCatTp5 (keratinocytes) were routinely cultured in Eagle's Minimum Essential 
Medium (EMEM, Gibco Life Sciences) supplemented with 10% fetal bovine serum 
(BioConcept), 100 units/mL penicillin and 100 µg/mL Streptomycin (Sigma Aldrich). 
Cells were maintained in a humidified atmosphere at 37 oC and 5% CO2. 
 
7.3.10  Cell viability assay 
 PrestoBlue cell viability reagent (Invitrogen) was used to determine cell viability. In 
accordance with the supplier's protocol, HaCatTp5 cells were seeded at a 
concentration of 7500 cells/well in a 96 well plate. After 24 h, 100 µL of medium was 
removed and replaced by 75 µL of fresh medium and 25 µL of different polymersomes 
(2 mg/mL) or PBS. The cells were incubated in the presence of polymersomes or 
control PBS for 1 more day in a humidified atmosphere at 37 oC and 5% CO2. The 
PrestoBlue reagent (20 µL) was added to each well and fluorescence at 615 nm was 
measured after 1 h at 37 °C using a Spectramax plate reader. The data was normalized 





7.3.11 Cell viability assay upon UV-irradiation 
 As described for cell viability assay without UV-irradiation, cells were incubated in 
presence of polymersomes for 1 day, prior being rinsed with 3 times with 200 µL of 
PBS to remove non-uptaken polymersomes. Then, 100 µL of PBS was added for UV-
irradiation (40 min with UV lamp from the cell hood). After, PBS was removed and 
100 µL of fresh media was added and cells incubated overnight. Cell viability was 
determined using PrestoBlue reagent as previously described for cell viability assay. 
The data was normalized to cells treated with same kind of polymersomes that have 
not been irradiated. 
 
7.3.12  Cells imaging 
 HaCatTp5 cells were seeded and incubated in the same conditions as described for 
cell viability assay, expect that model polymersomes encapsulating Atto-488 dyes were 
used. After 24 h of incubation in presence of polymersomes, cells were rinsed 3 times 
with PBS to get rid of non-uptaken polymersomes before imaging with a Zeiss LSM 
880 inverted microscope (Zeiss Axio Observer, Carl Ziss, Germany) with a water 
immersion objective C-Apochromate 40x/1.2 W korr FCS M27. The beam from 488 
nm argon laser was passed through a main beam splitter MBS488 and detection was 
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ssDNAa CCT CGC TCT GCT AAT 





 spacer-ssDNAa TTT TTT TTT TTC CTC 




ssDNAb TAA CAG GAT TAG CAG 





 spacer-ssDNAb TTT TTT TTT TTT AAC 
AGG ATT AGC AGA 
GCG AGG 
 
Table 3. ssDNA sequences used for the functionalization of polymersomes, enabling the clustering of 
the different vesicles via hybridization of the single strands. 
a) used for FCS measurements only 














Figure 10.2. (A) Normalized fluorescence correlation spectroscopy (FCS) autocorrelation 
curves of control Atto-488 labelled ssDNAb without DBCO group, in presence (blue) or 
absence (red) of empty polymersomes. Their respective fits are shown by the same-coloured 
solid lines. (B) TEM micrograph of empty polymersomes in presence of ssDNAb without 
DBCO. (C) Normalized FCS autocorrelation curves of free Atto-488 labelled ssDNAb (red) 
and corresponding ssDNAb linked polymersomes (blue). (D) Normalized FCS 
autocorrelation curves of Atto-488 labelled free spacer-ssDNAb (red) and corresponding 
spacer-ssDNAb linked polymersomes (blue). Their respective fits were shown by the same-









Figure 10.3. Quantification of ssDNAa per empty polymersome and DDC-Ncomp 
via FCS. (A) Normalized FCS autocorrelation curves of free DY-633 labelled 
ssDNAa (red) and empty polymersome conjugated with this labelled ssDNAa or 
spacer-ssDNAa after an overnight reaction at 4 °C. (B) The corresponding average 
number of ssDNAa or spacer-ssDNAa linkedon empty polymersome after the 
reaction. To quantify the amount of ssDNA per polymersome, first we measured the 
counts per molecule (CPM) for the free ssDNA- DBCO. Next we measured the CPM 
for the polymersomes with attached ssDNA. By dividing by the CPM of the ssDNA-
polymersomes by the CPM for free ssDNA-DBCO, and performing the 
corresponding error propagation, we obtained the number of attached ssDNA per 
polymersome ± SD. (C) Normalized FCS autocorrelation curves of free DY-633 
labelled ssDNAa (red) and corresponding ssDNAa linked DDC-Ncomp (blue). (D) 
Normalized FCS autocorrelation curves of free DY-633 labelled spacer-ssDNAa 
(red) and corresponding spacer-ssDNAa linked DDC-Ncomp (blue). Their respective 











Figure 10.4.  Effect of 2x molar Glutathione on the auto-oxidation 
process of Dopamine and L-DOPA in solution (1 mM in PBS), after 
24 h incubation at 37 °C. Dark brown/black colours of solution 
correspond to the formation of derivate molecules resulting from 
auto-oxidation of Dopamine and L-DOPA. 
Figure 10.5. HPLC chromatogram of dopamine and L-DOPA 










Figure 10.6.  Determination of percent conversion of L-
DOPA to dopamine in presence of increasing 
concentrations of free DDC (with BSA). The percent 
conversion was determined by HPLC, for DDC enzymes in 
presence of BSA and after incubation at 37°C for 24 h. 
Figure 10.7. Determination of SEAP production by HEKREWARD cells. (A) Determination 
of SEAP activity in cell supernatant to assess the concentrations of SEAP expressed by cells 
in response to increasing concentrations of Dopamine after 72 h of incubation. (B) 












Figure 10.8. Effect of absence of BSA on SEAP expression. (A) Determination of SEAP 
activity in cell supernatant in response to increasing concentrations of free DDC (without 
BSA) in presence of L-DOPA, after 72 h of incubation. (B) Processed data showing SEAP 
expression by cells as a function of increasing concentrations of free DDC. 
Figure 10.9. Assessment of SEAP production 















Figure 10.10. Comparison of the attachment of Dye-Ncomp at the surface of HEKREWARD 
cells, when functionalized or not with spacer-ssDNA, as imaged by CLSM with separated 










Figure 10.11. Attachment of polymersome clusters on the surface of 
HEKREWARD cells after 24h, recorded by CLSM. Top panel was used for the 
left 3D rendering (Figure 3.12) and bottom panel was used for the right 3D 








Figure 10.12. Cell attachment of clusters. (A) CLSM pictures from four different 
locations of 488-633-Ncomp clusters attached to the surface of HEKREWARD cells 
after 24 h of incubation, with separated DY-633 and Atto-488 channels, transmission 
channel and merged images (Scale bar = 20 μm). (B) Merged DY-633 and Atto-488 
channels of the four locations with colocalized regions19 appearing in white. 
Colocalization analysis of the four locations resulted in a Pearson’s coefficient of 0.83 













Figure 10.13.  Attachment of polymersome clusters on the surface of HEKREWARD cells, recorded 




























Figure 10.14.  1H-NMR of PDMS25-b-PMOXA10 in CDCl3. 
Figure 10.15. GPC elugram of PDMS25-b-
PMOXA10 in tetrahydrofuran, measured via 














Figure 10.16. TEM micrographs of (A) empty PMOXA19-PDMS25 









Figure 10.17.  Size determination via SLS (left) and DLS (right) of (A) empty 
PMOXA19-PDMS25 polymersomes (PDI = 0.163), (B) empty polymersomes with OmpF 
(PDI = 0.170), (C) GLuc Ncomp without OmpF (PDI = 0.159). SLS measurements show 
the DLS profile representing the hydrodynamic radius (Rh) of polymersomes at different 
angles (blue), the intensity at different angles (black) and the suitable MIE fit (grey) used 
to determine the radius of gyration (Rg). The ratio 0.775 < Rg/Rh ≤ 1 indicates a hollow 
sphere structure. DLS graphs show the Rh of polymersomes, measured at 173° angle, by 

















Figure 10.18. Luminescence production in the absence of 
coelenterazine substrate: GLuc Ncomp with OmpF in PBS 
(blue), GLuc Ncomp with OmpF in cell medium (dark blue), 
GLuc Ncomp without OmpF in PBS (purple), GLuc Ncomp 







Figure 10.19.  Activity of GLuc Ncomp with and without OmpF in presence of 
different coelenterazine concentrations in PBS and cell medium. (A) Activity of GLuc 
Ncomp with OmpF in PBS. (B) Activity of GLuc Ncomp with Ompf in cell medium. 
(C) Activity of GLuc Ncomp without OmpF in PBS. (D) Activity of GLuc Ncomp 
without OmpF in cell medium. (E) Luminescence background in PBS alone in 
presence of different concentrations of coelenterazine. (F) Luminescence background 








Figure 10.20. Activity of GLuc Ncomp with and without OmpF after incubation 
at 4 °C for 3, 7 and 14 days. (A) Activity of GLuc Ncomp with OmpF in PBS. (B) 
Activity of GLuc Ncomp without OmpF in PBS. (C) Activity of GLuc Ncomp with 
OmpF in cell medium. (D) Activity of GLuc Ncomp without OmpF in cell medium. 
(E) Remaining percentages of activity of free (grey) and encapsulated GLuc 
(cyan) in culture medium, upon storage at 4 °C in PBS. (F) Remaining 
percentages of activity of free (grey) and encapsulated GLuc (cyan) in culture 















Figure 10.21. Activity of GLuc Ncomp with and without OmpF after incubation 
at 37 °C for 3, 7 and 14 days. (A) Activity of GLuc Ncomp with OmpF in PBS. (B) 
Activity of GLuc Ncomp without OmpF in PBS. (C) Activity of GLuc Ncomp with 






Figure 10.22. Activity of non-encapsulated (free) GLuc after incubation at 4 °C or 
37 °C for 3, 7 and 14 days. (A) Activity of free GLuc at 4 °C PBS. (B) Activity of free 
GLuc at 4 °C in cell medium. (C) Activity of free GLuc at 37 °C in PBS. (D) Activity 
of free GLuc at 37 °C in cell medium. 
Figure 10.23. Luminescence production at higher 
concentration of GLuc Ncomp (50 µL of 2 mg/mL, final 
concentration = 1 mg/mL). Luminescence background 
of control samples: GLuc Ncomp without OmpF in PBS 
and cell medium and coelenterazine in PBS and cell 
medium. The ratio of the reactants is held constant (50 







Figure 10.24. Controls for luminescence production in 
cell supernatant: Cell supernatant with coelenterazine 
(pink), GLuc Ncomp without OmpF with coelenterazine 
(dark blue), cell supernatant without coelenterazine 
(green), GLuc Ncomp with OmpF without coelenterazine 
(orange), GLuc Ncomp without OmpF without 
coelenterazine (light purple), non-encapsulated (free) 
GLuc without coelenterazine (light blue). In the absence 
of coelenterazine, the signals remain below 30 RLU. 
Figure 10.25. Activity of free and encapsulated GLuc in presence of Proteinase K. 
(A) Activity of Free GLuc in absence (grey) and in presence (yellow) of Protease K, as 
compared to encapsulated GLuc in absence (blue) and in presence (purple) of 
Proteinase K. (B) Activity of free GLuc as compared to controls in presence of 
Proteinase K: PBS (grey), GLuc Ncomp without OmpF (blue), Free GLuc (yellow) and 
coelenterazine (purple). The samples have been incubated for 24 h at 37 °C with 0.1 








Figure 10.26. 1H-NMR of PDMS24-b-PMOXA12 in CDCl3. 
Figure 10.27. GPC elugram of PDMS24-b-PMOXA12 in 












Figure 10.28. TEM micrographs and corresponding DLS of (A) Melanin-












Figure 10.29. DLS showing the size of (A) Melanin-polymersomes (with 
tyrosinase), (B) PDA-polymersomes (with tyrosinase), (C) empty 
polymersomes rehydrated with PBS only, (D) Tyrosinase-
polymersomes, (E) Melanin-polymersomes (without tyrosinase) and (F) 

















Figure 10.30. Different photographs of glass vials containing solutions of encapsulated/free 


















Figure 10.31. CLSM images showing the morphology of aggregates of 
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